GUIDELINES FOR
UNIVERSAL EYE SCREENING
IN NEWBORNS
INCLUDING RETINOPATHY OF PREMATURITY

RASHTRIYA BAL SWASTHYA KARYAKRAM
Ministry of Health & Family Welfare
Government of India
March 2016
GUIDELINES FOR
UNIVERSAL EYE SCREENING
IN NEWBORNS
INCLUDING RETINOPATHY OF PREMATURITY

RASHTRIYA BAL SWASTHYA KARYAKRAM
Ministry of Health & Family Welfare
Government of India

March 2016
Eyes are windows to the brain and enable the child to see and learn. Being able to see gives tremendous input to the developing brain of a newborn. The critical period of brain development is in the first two years of life. Equal input from both eyes and clear focused image is essential for proper development of the brain. Cognitive development is delayed in children who have severely impaired visual function compared to children who have better vision.

Through early identification of the treatable conditions of the ocular system, such as congenital cataract, congenital glaucoma and retinoblastoma, followed by referral for prompt treatment can save a child’s eye and improve the quality of life through improving the quality of vision.

Additionally, Retinopathy Of Prematurity (ROP) is a potentially blinding eye disorder that primarily affects premature infants weighing about 1250 grams or less that are born before 31 weeks of gestation. The smaller a baby is at birth, the more likely that baby may develop ROP. This disorder—which usually develops in both eyes—is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. Infants with ROP are considered to be at higher risk for developing certain eye problems later in life.

Studies from India have reported ROP in 20-22% screened neonates. Given the huge birth cohort in the country, this would translate to substantial numbers. Considering the significance of the problem, Guidelines for Universal Eye Screening including ROP in newborns has been developed which lays due focus on comprehensive eye screening with special focus on ROP in high risk babies.

This manual is suitable for various health care functionaries for the effective implementation of screening & management of eye disorders in newborn including ROP.

I am certain that these guidelines will prove to be useful and that States/UTs would do all that is necessary to ensure its implementation in right earnest.

Dr. Rakesh Kumar
Joint Secretary, RCH
Ministry of Health & Family Welfare
Government of India
New Delhi
It is estimated that currently there are approximately 270,000 blind children in India. The major causes of blindness in children include cataract, Retinopathy Of Prematurity (ROP), and Vitamin A deficiency. Approximately half of all the childhood blindness can be avoided or treated.

There are many causes of vision loss. Some cause more severe loss than others. One of the most common conditions is ROP, an eye problem that occurs mainly in babies born before 31 weeks of pregnancy. About 90 percent of all infants with ROP are in the milder category and do not need treatment. However, infants with more severe disease can develop impaired vision or even blindness.

In India the incidence of ROP has been reported at 24–47% among high risk preterm infants. The improved survival of preterm and small-for-date neonates in our country, especially after the operationalisation of NICUs and SNCUs, has led to an increase in the incidence of ROP in infants.

Timing is one of the important factors that make the treatment successful in ROP, because the disease can advance very quickly and delayed treatment often reduces the chances of success. If we are able to identify the eye disorders right at birth and/or during the stay of High Risk Babies at SNCUs/NICUs we are utilising the window of opportunity to treat the disorder at the earliest and thus preventing developmental delays in these children.

The current manual for health care functionaries has got two components: Technical component that deals with primary management of all disorders in newborn and ROP screening, interpretation & management of ‘at risk new-borns’ and Operational component on implementation of Universal Vision and ROP screening and Management.

We hope this manual will be a valuable reference for the Paediatrician/Medical officers of SNCU, SNCU Staff Nurse, Optometrist of the DEIC, Ophthalmologist of District Hospital/ Private Hospital to identify and manage eye related disorders in newborns and also for the Programme managers at the State, District & Block Levels.

Dr. Ajay Khera
Deputy Commissioner & Incharge
Ministry of Health & Family Welfare
Government of India
New Delhi
Guidelines for Universal Eye Screening in newborns including Retinopathy Of Prematurity (ROP) is a unique document which comprehensively focuses on identification of all the treatable conditions of the ocular system. Some are present at birth for e.g., microphthalmos, anophthalmos, corneal opacity, congenital cataract, congenital glaucoma and some are acquired during the neonatal period for e.g., Retinopathy Of Prematurity, Ophthalmia neonatorum.

ROP affects low-birth-weight premature infants and can lead to blindness; the incidence of ROP has increased in our country, as smaller and younger babies are surviving through initiatives like SNCU.

This document is to guide and support medical officers, paediatricians, optometrists and ophthalmologists in the country towards timely identification, primary management and referral of all treatable eye disorders including ROP in New-born and has been prepared with valuable inputs from experts across the country.

We would like to acknowledge the support of various experts and contributors who have given their inputs which immensely helped to give this manual a final shape.

I wish success and pledge my unstinting support towards implementation of this initiative.

Dr. Arun Kr. Singh
National Advisor, RBSK
CONTRIBUTORS

- Dr. Mangat Dogra, PGI Chandigarh
- Dr. Pranab Das, Calcutta Medical Research Institute
- Dr. Ramesh Kekunnaya, LV Prasad Eye Institute, Hyderabad
- Dr. Clare Gilbert, Professor, London School of Hygiene and Tropical Medicine
- Dr. G.V.S. Murthy, Director, IIPH, Hyderabad
- Dr. Lea Hyvarinen, Professor, University of Dortmund & University of Helsinki
- Dr. Praveen Kumar, PGI Chandigarh
- Dr. Ashok Deorari, AIIMS, New Delhi
- Dr. Anand Vinekar, Narayana Netralaya, Bangalore
- Dr. Namita Jacob, Chetana Charitable Trust, Chennai
- Dr. Pradeep Sharma, RP Centre, AIIMS, New Delhi
- Prof. Dr. Parijat Chandra, RP Centre, AIIMS, New Delhi
- Dr. P. Vijayalakshmi, Chief- Paediatric Ophthalmology, Aravind Eye Hospital, Chennai
- Dr. Subhadra Jalali, LV Prasad Eye Institute
- Dr. Suchandra Mukherjee, IPGMER, Kolkata
- Dr. Rajan Shukla, PHFI

Compiled and Edited - Dr. Arun Kumar Singh (National Advisor-RBSK)
ABOUT
THE DOCUMENT

This document has been developed for various health care functionaries for the effective implementation of screening & management of eye disorders in newborn including Retinopathy Of Prematurity.

The document has got two components viz., Technical & Operational

1. **Technical Component** for Pediatrician/Medical officers of Special Newborn Care Unit (SNCU), SNCU Staff Nurse, Optometrist of the DEIC and the Ophthalmologist of District Hospital/ Private Hospital on:
   a. **Universal Eye screening** in all newborns including referral guidelines (Pediatrician/Medical officers of SNCU, SNCU Staff Nurse, Medical officers and Staff nurse/ANM at all delivery points)
   b. **Importance of ROP screening, Initial Steps:** preparing newborns for ROP screening, Timing of referral and significance of Aggressive Posterior Retinopathy Of Prematurity (APROP) (Pediatrician/Medical officers of SNCU, SNCU Staff Nurse, Optometrist attached to the District Early Intervention Center)
   c. **ROP screening, interpretation and management** of “at risk newborns” (by Ophthalmologist of District Hospital/ Private Hospital)
   d. **Ocular history: Identifying Risk factors for vision impairment** (in future) **even if eye examination is normal at birth:** follow up of such children at the **DEIC/District Hospital -Ophthalmology OPD, to be mentioned in the newborn discharge** (Pediatrician/Medical officers of SNCU, SNCU Staff Nurse, Optometrist attached to the District Early intervention center)

2. **Operational Component** on Implementation of Universal Vision & ROP screening and management for:
   a. State representative of RBSK, National Programme for Control of Blindness (NPCB), Child Health/ SNCU
   b. District Chief Medical officer
   c. District Nodal officer (RCH)
   d. Administrative head of the District Hospital/ Medical College
   e. Representative from NPCB
   f. Representative from Local Ophthalmic association
   g. DEIC Manager

“Pediatricians are the first line of defense in the newborn’s world”

“Knowing is not enough - we must apply
Willing is not enough - We must do”
## TABLE OF CONTENTS

**INTRODUCTION** ............................................................................................................................................. xv

1. Burden of Childhood Blindness .................................................................................................................. xv
2. Rashtriya Bal Swasthya Karyakram (RBSK) .......................................................................................... xvi
3. Target Group under Universal Eye Screening .......................................................................................... xvii

**GUIDELINES FOR: UNIVERSAL EYE SCREENING OF NEWBORNS** ................................................................. 1

1. Universal Eye Examination in Newborns ................................................................................................. 1
2. What is Vision? How does the Eye Work? .............................................................................................. 1
3. Brief Overview of Eye Anatomy, Physiology and Terminology ............................................................. 3
4. Eye Examination ...................................................................................................................................... 8
5. Tools Required for Newborn Eye Examination ..................................................................................... 9
6. Screening cum Referral Card .................................................................................................................. 21
7. Pictorial Tool for Identification of Eye Defects ..................................................................................... 22

**GUIDELINES FOR OPERATIONALISING RETINOPATHY OF PREMATURITY (ROP) .................................. 25**

1. Introduction .............................................................................................................................................. 26
2. Classification of ROP: Location/Extent/Severity ..................................................................................... 27
3. Risk Factors for ROP ............................................................................................................................... 34
4. Screening of ROP ..................................................................................................................................... 35
5. Management of ROP ............................................................................................................................... 42
6. Follow-up Examinations in SNCU/NICU .............................................................................................. 47
7. Complications of ROP ............................................................................................................................ 47
8. Issues, Follow up and Counselling .......................................................................................................... 47
9. Other Modalities of Treatment ............................................................................................................... 48
10. ROP Recording Form ............................................................................................................................ 51
11. Preventive Measures ............................................................................................................................. 52
12. Quality Improvement ............................................................................................................................. 53
13. Strategies for Control of Visual Loss from ROP ................................................................................... 54
14. Exercise on ROP ................................................................................................................................... 55

**INTEGRATED APPROACH TO UNIVERSAL EYE SCREENING** ........................................................................ 63
1. BURDEN OF CHILDHOOD BLINDNESS

The major causes of blindness in children vary widely from region to region, being largely determined by socioeconomic development, and the availability of primary health care and eye care services. The prevalence of blindness in children is 6.5 (95% confidence interval 5.1-8.2) per 10,000 children based on population based studies from South India. As per current estimates there are 320,000 blind children (<16 years) in India. (Murthy et. al. IJO.2008;56).

Causes of severe visual impairment among children in India:

1. Whole globe: Congenital globe anomalies (microphthalmos, anophthalmos) and coloboma accounts for 20.7% to 25%.
2. Cornea: Corneal scarring (mostly Vitamin A deficiency, infection) accounts for 11.6% to 26.4% of the childhood blindness.
3. Lens: Cataract, uncorrected aphakia and amblyopia account for 10.9% to 12.3%.
4. Retina: Retinal conditions, mainly ROP and hereditary retinal dystrophies account for 19.3% to 22%.
5. Optic nerve: Optic nerve disorders account for 5-6%.

The major causes of blindness in children include Cataract, Retinopathy Of Prematurity (ROP), and Vitamin A deficiency. Approximately half of all childhood blindness can be avoided or treated overall the commonest causes of blindness in children in India which could be diagnosed in neonatal period are as follows:

1. Congenital abnormalities of globe anophthalmos, microphthalmos and coloboma
2. Congenital clouding or Corneal opacities
3. Congenital cataract
4. Congenital glaucoma
5. Retinopathy Of Prematurity (acquired disorder in pre-term children)
6. Retinal conditions, mainly hereditary retinal dystrophies.
7. Ophthalmia neonatorum (acquired during the neonatal period)
8. Cortical visual impairment (acquired during the perinatal period)
9. Congenital anomalies of the whole eye, usually of unknown cause, but where genetic factors may play a role, for e.g., Retinoblastoma

10. Congenital infections acquired during pregnancy, for e.g., cataract due to congenital rubella. Most of these conditions can be identified during the newborn period, some would be classified as ‘at risk newborns’ and would require repeated examination and follow up.

2. RASHTRIYA BAL SWASTHYA KARYAKRAM (RBSK)

Defects at Birth, Deficiencies, Diseases specific to childhood and Developmental delays including disabilities, “4Ds”, can either lead to untimely death of a child or a survival with poor developmental outcomes. Such long lasting adverse health outcomes can be addressed only through early screening and timely management.

Extending preventive and promotive health as an approach for selected health conditions along with provision of free curative management, will help the marginalized and underprivileged population by reducing their out of pocket expenditure thereby influencing public health expenditure. This, in the long run, will improve the quality of our national human resource pool.

Keeping this in view, Ministry of Health and Family Welfare, introduced “Child Health Screening and Early Intervention Services” as Rashtriya Bal Swasthya Karyakram-RBSK under National Health Mission. These services under RBSK are to cover all the thirty selected health conditions through their screening, early detection & free management, for children from birth to 18 years of age.

Selected Health Conditions for Child Health Screening & Early Intervention Services under RBSK

<table>
<thead>
<tr>
<th>Defects at Birth</th>
<th>Deficiencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Neural tube defect</td>
<td>11. Anemia especially Severe anemia</td>
</tr>
<tr>
<td>2. Down’s Syndrome</td>
<td>12. Vitamin A deficiency (Bitot’s spot)</td>
</tr>
<tr>
<td>3. Cleft Lip &amp; Palate / Cleft palate alone</td>
<td>13. Vitamin D Deficiency (Rickets)</td>
</tr>
<tr>
<td>4. Talipes (club foot)</td>
<td>14. Severe Acute Malnutrition</td>
</tr>
<tr>
<td>5. Developmental dysplasia of the hip</td>
<td>15. Goiter</td>
</tr>
<tr>
<td>6. Congenital Cataract</td>
<td></td>
</tr>
<tr>
<td>7. Congenital deafness</td>
<td></td>
</tr>
<tr>
<td>8. Congenital heart diseases</td>
<td></td>
</tr>
<tr>
<td>9. Retinopathy Of Prematurity</td>
<td></td>
</tr>
<tr>
<td>10. Strabismus and eye movement disorder (specially nystagmus)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Childhood Diseases</th>
<th>Developmental delays and Disabilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. Skin conditions (Scabies, fungal infection and Eczema)</td>
<td>22. Vision Impairment</td>
</tr>
<tr>
<td>17. Otitis Media</td>
<td>23. Hearing Impairment</td>
</tr>
<tr>
<td>21. Convulsive disorders</td>
<td>27. Language delay</td>
</tr>
<tr>
<td></td>
<td>28. Behavior disorder (Autism)</td>
</tr>
<tr>
<td></td>
<td>29. Learning disorder</td>
</tr>
<tr>
<td></td>
<td>30. Attention deficit hyperactivity disorder</td>
</tr>
</tbody>
</table>

31. Others: Congenital Hypothyroidism, Sickle cell anemia, Beta thalassemia (Optional)
3. TARGET GROUP UNDER UNIVERSAL EYE SCREENING

The primary target age group is the early neonatal period which is the most critical time for identification of any eye related disorder and its management. The broad groups are as under:

<table>
<thead>
<tr>
<th>Categories</th>
<th>Age group</th>
<th>Tools</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNCU graduates for Universal Eye Screening</td>
<td>Birth till discharge</td>
<td>Pictorial tools</td>
</tr>
<tr>
<td>Babies born at all delivery points (other than SNCU admissions) for Universal Eye Screening</td>
<td>Birth till discharge (within 48-72 hours of delivery)</td>
<td>Pictorial tools</td>
</tr>
<tr>
<td>Preterm Newborns for ROP including SNCU admissions for Universal Eye Screening plus ROP</td>
<td>First screening at 4 weeks of birth; those born before 30 weeks to be done at 2-3 weeks</td>
<td>Pictorial tools plus ROP Screening Instruments</td>
</tr>
</tbody>
</table>

This Screening would be carried out by medical officers, ANM of the delivery points, pediatrician and staff nurse of the SNCU with the help of DEIC optometrist. Management would be done by the ophthalmologist.

Timing is one of the important factors that make the treatment successful in eye related disorders, because some disease can advance very quickly and delayed treatment often reduces the chances of success. If we are able to identify the eye disorders right at birth and/or during the stay of High Risk Babies at SNCUs/NICUs we are utilizing the window of opportunity to treat the disorder at the earliest and thus preventing developmental delays in these children.
Guidelines for:
Universal Eye Screening of Newborns

Universal Eye Examination in Newborns

Vision is one of our five senses. Being able to see gives tremendous access to the developing brain of the newborn, helping them to learn about the world around—people’s faces and the subtleties of expression; what different things look like and how big they are, and the physical environments where the growing infant lives and moves, including approaching hazards. When a child has a visual impairment, it is a cause for immediate attention. That’s because so much learning typically occurs visually.

The fact that 40 per cent of the human brain is devoted to processing visual information shows the complexity and importance of this remarkable sense.

What is Vision? How Does the Eye Work?

Vision is the perceptual system that is most suited for gaining information about the environment, particularly information about shape and space. Vision also is an important factor in early interactions between the infant and the parent(s). It is not surprising that children who have reduced sensory information because of vision impairment often find it more difficult to acquire various developmental skills and therefore demonstrate delays in development. Cognitive development is delayed in children who have severely impaired visual function, compared with children who have better vision. Early cognitive development and motor development are interrelated and can affect a child’s ability to interact with objects and people. In particular, object concept (understanding the relatedness of objects to other objects, events, persons, and experiences) and object permanence (understanding that something still exists even when it is not present) tend to be delayed in young children who are blind. Blind children’s delays in obtaining the object concept...
can then result in delays in understanding other concepts. Good vision is essential for proper physical development and educational progress in growing children. The visual system in the young child is not fully mature. Two things are critical:

a. Equal input from both eyes is required for proper development of the visual centers in the brain.

b. If a growing child’s eye does not provide clear focused image to the developing brain, then permanent irreversible loss of vision may result.

**Eye and Vision:** Vision occurs when the eye receives images and transmits them to the brain. Vision is a complex process that involves the eye, the brain, and the pathways between them. The eye has a system similar to a video camera connected to a computer that controls the amount of light allowed in and then focuses light rays onto the back of the eye to be transmitted to the brain. This system includes the eyelids, the cornea (a clear layer that covers the front of the eye), the iris (the circle of color around the pupil), the pupil (the black center of the eye that controls the amount of light), and a lens (the part of the eye that focuses the image).

Visual impairment can be the result of a problem either in the eye itself or in the visual nervous system. A child’s diminished ability to see may be related to a problem with any one or more of the following:

- allowing the light to pass through the eye
- focusing the light appropriately on the retina
- causing a reaction to occur within the photoreceptors of the retina
- transmitting the information via the optic nerve and visual pathways
- receiving/interpreting visual information by the brain
- integrating the information and providing appropriate feedback to the eye and extraocular muscles so that fixation can be maintained on the target

**Newborns considered high risk for vision impairment** even if initial examination of eye is normal include:

- Premature infants
- Those with a family history of congenital glaucoma or congenital cataracts or retinoblastoma in childhood, retinal dystrophy/degeneration or systemic diseases associated with eye problems
- Those with a family history of strabismus, amblyopia and/or sensori-neural hearing loss
- When any opacity of the ocular media is seen during newborn examination
- Infants with neuro-developmental delay
Another important part of the eye is the retina. The retina is at the back of the eye, and it contains different types of light-sensing nerve cells generally classified as photoreceptors.
I. Sclera

The tough coat of the eyeball is called the sclera. It is white.

II. Conjunctiva

The conjunctiva is a thin, transparent mucous membrane which lines the under surface of the upper and lower eyelids and the front of the eye, except the cornea. Small blood vessels can be seen in the conjunctiva. If infection is present the conjunctiva becomes red and inflamed.

III. Cornea

The front surface of the eye, the cornea, is a transparent, smoothly curved surface which focuses light entering the eye, providing most of the eye’s focusing power of the eye. The surface is kept smooth and in good condition by tears which are spread over the surface by normal blinking. Loss of transparency due to scarring is a common cause of visual impairment in children. A scarred or white cornea can not only cause a cosmetic problem for the child but also affects the cognitive development.

At birth the cornea should be completely clear. Check for abnormal corneal size, normally 9-10.5 mm at birth.

IV. IRIS and PUPIL

The colored part of the eye is the IRIS. In Indians it is brown. The Iris has a hole in the center called the PUPIL through which light enters the eye. In bright sunlight the pupil becomes very small; in darkness, the pupil becomes larger.
Controlling the amount of light entering the eye, the pupil can also assist in focusing light, to give a better “depth of field”.

The colored part of the eye that regulates the amount of light entering the eye is Iris.

Lens is the clear part of the eye behind the iris that helps to focus light on the retina.

Retina is the light-sensitive tissue lining in the back of the eyeball that sends electrical impulses to the brain.

V. Lens

The lens of the eye lies just behind the iris and pupil. It should be complete transparent and in a healthy eye it is impossible to see the lens with a torch. The lens is also responsible for focusing the light that enters the eye. The lens changes shape for near vision, as a result of contraction of the muscles in the ciliary body. This process is known as accommodation.

Loss of transparency in the lens can be due to a wide variety of causes and is called cataract. Although it is much more common in older people, it is also a major cause of visual impairment in children worldwide.

Congenital cataract needs to be operated as early as possible as a delay can lead to permanent loss of vision.
VI. Fluids inside the eye

Between the cornea and the lens is the anterior chamber which is filled with a transparent watery fluid, called aqueous humour. This fluid is constantly produced by the ciliary body, and it escapes from the eye through channels at the front of the eye. If the fluid cannot escape then the pressure inside the eye increases, leading to a condition called glaucoma, which can lead to blindness.

Signs which suggest glaucoma in young children are an abnormally large eye, with a cloudy or opaque cornea. The eye may or may not be red.

The space between the back of the lens and the back of the eye is filled with a clear gel called the vitreous humour.

VII. Retina and optic nerve

The function of retina is to convert light energy into nerve impulses which are sent to the brain via the optic nerve where the perception of vision takes place. It is the photoreceptors in the retina that convert the light into "nerve impulses" that travel through the optic nerve to the brain. The brain then interprets these nerve impulses and produces an image. Not only is an image produced, but also information is received about important characteristics of the image, such as its placement, motion, and localization in space.

However Cornea, pupil, lens and all the structures outlined earlier need to produce a clear and focused image on the retina, which is the “light sensitive” part of the eye, and is analogous to the film in a camera. The major landmarks are the Optic disc which is the exit of the optic nerve, and the Macula which is the area about 4mm across and which includes the Fovea (the most important point in the retina for detailed central vision) at its center. The retina is divided into two layers, the inner “nerve” or neural layer or photoreceptors of retina and the outer pigment layer. The neural retina contains the cells called Rods and Cones or photoreceptors which convert light into electrical signals which are eventually interpreted by the brain as a visual image. This process depends on the presence in the rods and cones of substances called photo pigments which change the shape of their molecules when they absorb light energy.

a. Rod cells are the receptors for night vision and ‘see’ everything as shades of gray.

b. Cones are the receptors for daylight vision and respond to colors, movement, and high- and low-contrast.

c. The density of the rods and cones varies in different parts of the retina. The rods are absent at the fovea, the cones on the other hand are most dense at the fovea.

d. Both rods and cones contain photo pigments (light-sensitive molecules), but whereas all rods contain the same photo pigment, the cones contain three different types of photo pigment. One group of cones responds especially to blue light, one group to red and one to green light.

VIII. Visual cortex (or striate cortex)

The brain interprets the nerve impulses transmitted from the retina via the optic nerve and produces an image.

a. Primary visual cortex: The striate cortex or Primary visual cortex is where nervous impulses from the retina are converted into an image of the visual world. But that is not enough. One wants important characteristics of the image such as its placement, depth and motion including the colour, form and texture of the object.
b. Thus there are two pathways: **Dorsal pathway** going to the parietal lobe which tells where the object is including, depth and motion and the **Ventral pathway** going to the inferior temporal lobe that tells about the form and texture. This information allows a person to fixate on an object and identify it. There are over 30 areas in the brain that are involved in receiving and translating visual information.

*Primary visual cortex: Broadmann area 17 makes up the primary visual cortex and then it travels along the dorsal pathway and ventral pathway*

**Primary Visual Cortex**

*Medial View*

![Primary Visual Cortex Diagram](image)

*Processing Visual Information on Depth, Motion, Form and Colour*

*Parallel Pathways*
EYE EXAMINATION

Examination of the eyes immediately after birth should be part of routine examination at birth.

Purpose of eye examination of newborn

**Early Eye examination** is vital for the detection of those conditions, which if not treated promptly can not only result in blindness, but also lead to problems with cognition or school performance or may signify serious systemic disease or at worst threaten the child’s life.

**The critical period of brain development** happens in the first two years of life. Of the total 18 cm gain in head circumference of an individual during the lifetime, 12 cm increase happens in the first year of life and 3 cm in the second year of life. Eyes are a window to the brain and help in development during the critical period.

Through **early identification** of the **treatable conditions** of the ocular system, such as congenital cataract, congenital glaucoma and retinoblastoma, followed by referral for prompt treatment can save a child’s eye and improve the quality of life through improving the quality of vision.

**Early identification** of those conditions which are **not treatable**, such as structural abnormalities of the eyes, requires early rehabilitation in the critical period as this would help to promote motor and psychosocial development of the growing child enabling the child to live a fuller life.

Steps in eye examination

- Ocular history
- External examination of the eyes
- White reflex with a torch
- Red reflex examination with an ophthalmoscope

Ocular history

Ask the parents the following:

- Do either of the parents have an eye condition which was present since birth?
- Do any brothers or sisters of the child have an eye or vision problem?
- Did the mother have a rash during the pregnancy of this child?

External Examination of the Eye:

Needs to learn to focus on

- Examining the eye with a torch
TOOLS REQUIRED FOR NEWBORN EYE EXAMINATION:
AGE SPECIFIC SCREENING: NEWBORN

1. **Ocular history: Identifying Risk factors for vision impairment for future follow up** even if initial eye examination is normal at birth:

   a. **Family history of conditions** causing blindness or severe visual impairment (e.g., Congenital cataracts, Congenital glaucoma, Congenital squint, Congenital nystagmus, Familial Exudative Vitreoretinopathy, Retinoblastoma, and certain metabolic and genetic diseases)

   b. **Family history** of Strabismus, Amblyopia and/or sensori-neural hearing loss

   c. **Prenatal and birth history:**
      - Birth asphyxia,
      - Intrauterine infection,
      - Prematurity, especially low birth weight babies (less than 2000 gm)

   d. **Congenital conditions:**
      - Albinism
      - Brain lesion noted on newborn brain imaging
      - Chromosomal abnormalities, such as Down syndrome

   e. **Other structural birth defect especially involving the facial structures**

   f. **Others: Hydrocephalus** *Infectious disease (e.g., toxoplasmosis, cytomegalovirus, herpes simplex) *Periventricular Leukomalacia (PVL)

   g. **Any stage of ROP even if it regresses**

**Discharge slip for the newborn must accompany with an advice for follow up for vision examination, even if initial eye examination is normal at birth**

2. **External examination of the eye:**

   a. External examination of the eye is a general inspection of the eye including the orbits, globes, eyelids, eyelashes, tear sacs, and conjunctiva.

   b. External examination for any abnormality with Sclera, Cornea, Iris, Pupil, Lens

   a. Pictorial tool at all delivery points

   b. Screening cum referral card for eye problems
3. Use Torch light or Flash light to examine:

   a. **External evaluation** for obvious ocular malformations and infections

   b. **Pupillary examination: Light reflex**: Pupillary reaction is evaluated by testing constriction of each pupil both when it is stimulated directly by light and when the other eye is stimulated by light (consensual light reflex).

   c. **Pupillary examination: for white reflex**

   White pupillary reflex is the whitish appearance of pupil. This condition is also known as leukocoria. (From the Greek “leukos” meaning white and “kore” meaning pupil) and is the name given to the clinical finding of a white pupillary reflex. It can occur in number of conditions. Leukocoria can be caused by abnormalities in the lens (e.g., cataract), vitreous (e.g., hemorrhage), or retina (e.g., retinoblastoma). Following are the causes of white pupillary reflex in early life.

1. **Congenital Cataract**
2. **Congenital glaucoma**
3. **Anterior Persistent Hyperplastic Primary Vitreous (APHPV)**: Developing lens has nutritional vascular supply which regresses after birth. In APHPV primary vitreous of fetal life persists along with the vascular after birth. It is present behind the lens and don’t allow light rays to reach retina and give white pupillary reflex on examination.

5. **Familial Exudative Vitreoretinopathy, Autosomal Dominant**: Familial exudative vitreoretinopathy (FEVR) is a genetic eye disorder affecting the growth and development of blood vessels in the retina of the eye. This disease can lead to visual impairment and sometimes complete blindness in one or both eyes. FEVR is characterized by exudative leakage and hemorrhage of the blood vessels in the retina, along with incomplete vascularization of the peripheral retina, and can easily be confused with retinopathy of prematurity in premature infants.

6. **Retinoblastoma**: It is a congenital tumor of retina. It is a life threatening malignant condition and it usually occurs within first three years of life.

7. **Corneal Opacity**
4. See Red Reflex through Direct Ophthalmoscope:
   a. Red reflex test: The red reflex is the red light reflection seen when examining the eye with an ophthalmoscope. This test is used to determine whether there is an opacity (cloudiness) of the cornea, cataract, or a retinal detachment or disorder.
   b. Binocular red reflex: The Bruckner test is a comparison of the red reflexes when viewed from both eyes at the same time. This test is used to assess symmetry of alignment and refractive errors of the eyes.

Unequal red reflex or absence of red reflex: 1. Congenital Cataract 2. Anterior Persistent Hyperplastic Primary Vitreous (APHPV) 3. Familial Exudative Vitreoretinopathy (FEVR) 4. Retinoblastoma 5. Severe Anisometropia and Strabismus

Universal eye screening for all newborns: Key points to be followed

<table>
<thead>
<tr>
<th>Inspection and examination using torch and Direct Ophthalmoscope</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eye lid &amp; facial examination</strong></td>
<td>Any gap in the eyelid, any swelling, drooping eyelids,</td>
</tr>
<tr>
<td><strong>Any Facial marks</strong></td>
<td>Any pigmented marks around the eye</td>
</tr>
<tr>
<td><strong>Look at the eyes</strong></td>
<td>One or both eyes is too small</td>
</tr>
<tr>
<td></td>
<td>One or both eyes is not developed</td>
</tr>
<tr>
<td></td>
<td>One or both eyes is too big</td>
</tr>
<tr>
<td><strong>Conjunctiva</strong></td>
<td>Redness with discharge</td>
</tr>
<tr>
<td><strong>Sclera (Outer circle):</strong></td>
<td>Abnormal growth (Dermoid) or Blue sclera</td>
</tr>
<tr>
<td><strong>look for</strong></td>
<td>Any abnormality</td>
</tr>
<tr>
<td><strong>Cornea (Middle Circle):</strong></td>
<td>Large cornea (Megalocornea, Congenital glaucoma)</td>
</tr>
<tr>
<td><strong>Look for Corneal size and Transparency</strong></td>
<td>Small cornea (Micro cornea)</td>
</tr>
<tr>
<td></td>
<td>Hazy cornea (corneal opacity, congenital glaucoma)</td>
</tr>
<tr>
<td></td>
<td>Gap in the iris (Coloboma)</td>
</tr>
<tr>
<td><strong>Pupil (Inner circle):</strong></td>
<td>Pupil circle abnormal shape (Coloboma)</td>
</tr>
<tr>
<td></td>
<td>White reflex (with a torch): congenital cataract, any abnormal lesion arising from vitreous and retina.</td>
</tr>
<tr>
<td></td>
<td>Red reflex with Direct Ophthalmoscope</td>
</tr>
<tr>
<td></td>
<td>Abnormal: Congenital cataract, any abnormal lesion arising from vitreous and retina.</td>
</tr>
</tbody>
</table>
OCULAR ABNORMALITIES WHICH MAY BE PRESENT AT BIRTH

Abnormalities of the eye which can readily be detected by examination of the eye:

- **Eyelid abnormalities**: the eyelids may be too narrow, or the eyelid(s) may be droopy. (Can be familial)
- **Abnormally small eye** (microphthalmos) or **absent eye** (anophthalmos) from birth. These conditions can affect one or both eyes. (Can be familial)
- **Coloboma**, where a portion of the structure of the eye is missing. Can be familial; commonly involves eyelid, iris, choroid, retina. In coloboma iris, pupil will be irregular with a defect in inferior nasal quadrant.
- **Congenital glaucoma**, where the pressure inside the eye(s) is too high. In the newborn this can lead to an eye that is larger than usual. The cornea may also be cloudy or opaque.
- **Corneal opacity**. Very occasionally infants can be born with cloudy or opaque corneas. This is not caused by Vitamin A deficiency which affects older children. (Can be familial)
- **Congenital cataract**

Abnormalities of structures inside the eye which may only be detected by assessing the red reflex at birth

- Congenital cataract, where the lens of the eye is cloudy. This can affect one or both eyes, and occurs in around one in 3000 births. Can be familial.
- Retinoblastoma, a rare but life-threatening malignant condition of the retina. This can be present at birth or become apparent during the first few weeks of life. It can be familial.

I. Inspect the eyes:

- Note the **position/spacing and size of the eyes**, width of palpebral fissures.
- **Asymmetry of the eyes** may be the result of prominent epicanthal folds, a difference in the size of the globes, or ptosis.
- Any redness, discharge or lid matting to rule out conjunctivitis and nasolacrimal duct obstruction
- Abnormal slant, widened or narrow palpebral fissures can be part of a **syndrome complex due to chromosomal or genetic disorder**.

For normal eye, the inner canthal distance is equal to palpebral fissure length
Guidelines for: Universal Eye Screening of Newborns

II. Inspect eyelids and face:

a. Swelling of the eye lids is Common after birth
b. Check for any gap in the eyelids: Coloboma of eyelids
c. Check for any hemangioma of the eyes (Port wine stain)

Port wine stain

A port wine stain is a vascular birthmark caused by abnormal development of blood vessels in the skin. A port wine stain is sometimes referred to as a capillary malformation. A port wine stain is a flat, red or purple mark on the skin that is present at birth. Over time, the port wine stain may become thicker, darken and develop a ‘cobblestone’ appearance with raised bumps and ridges.

a. Glaucoma: Children with a port wine stain around the eye have an increased risk of glaucoma. About one in four of these children develop glaucoma. Glaucoma is raised pressure within the eye, which can lead to blindness if it is not treated. Treatment is usually by eye drops and occasionally an operation.

b. Sturge-Weber syndrome: If a newborns port wine stain is on the skin around the eye, forehead or scalp, there is a chance that he or she may have a condition called Sturge-Weber syndrome. Besides the port wine stain affecting the skin, it may also involve blood vessels over the surface of the brain, which can cause seizures (fits or convulsions). If there is any suspicion that your child is at risk of Sturge-Weber syndrome, they will need to be checked over by a neurologist.

c. Klippel Trenaunay syndrome: A large port wine stain on the arm or leg might be associated with extra growth of that limb and is referred to as Klippel Trenaunay syndrome. This may need a multidisciplinary review by dermatologists, laser specialists, and general, orthopedic and vascular surgeons.

d. Proteus syndrome: Port wine stains can be associated with Proteus syndrome, which causes extra growth in some parts of the body, mainly the hands and knees, but also others. This extra growth can affect movement, particularly if a joint is involved. Children with Proteus syndrome need regular checkups with a multidisciplinary team including dermatologists, general, orthopedic and vascular surgeons and laser specialists.
III. Look at the eye

<table>
<thead>
<tr>
<th>Abnormally small eye (microphthalmos) or absent eye (anophthalmos) or Buphthalmos (large eye)</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td>Bilateral anophthalmos</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anophthalmos – the eye socket is empty with no evidence of an eye. Both eyes affected or only one eye.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>Microphthalmos</td>
</tr>
</tbody>
</table>

Microphthalmos: or Small Eye syndrome is a disorder in which one or both the eyes of the newborn baby are underdeveloped. Various genetic factors, which affect the early development of the eyes, are found to be responsible for this condition. Certain environmental factors may also contribute to the condition. Children with microphthalmos present with visual disturbances and learning disabilities.

Buphthalmos is a descriptive term which simply means an enlarged eyeball or ocular globe (usually without deformation or and intrinsic mass lesion).

Primary congenital glaucoma typically presents in the neonatal period with the classic triad of tearing, photophobia and Blepharospasm (involuntary twitching, blinking or closure of the eyelids) + conjunctival redness, corneal enlargement and corneal clouding.
IV. Look at the conjunctiva

Red eye with discharge: Conjunctivitis is an inflammatory disease characterized by conjunctival erythema, swelling, and discharge. Ophthalmia Neonatorum (ON), also called neonatal conjunctivitis, is an acute, mucopurulent infection occurring in the first 4 weeks of life, affecting 1.6% to 12% of all newborns, caused by chemical, bacterial, or viral processes.

Aseptic neonatal conjunctivitis: Chemical conjunctivitis accounts for most cases presenting as a mild, purulent conjunctivitis within the first 24 hours of life. It is most commonly associated with silver nitrate prophylaxis, or secondary to prophylaxis with other agents such as erythromycin or tetracycline. Chemical conjunctivitis is a self-limiting condition that does not require any diagnostic tests or treatment.

Bacterial and viral infections are major causes of septic neonatal conjunctivitis. Infants may acquire these infective agents as they pass through the birth canal during the birth process. e.g. gonococcal conjunctivitis.

Chlamydia trachomatis: The incubation period is typically 1 week after delivery; however, it varies from 5 to 14 days or earlier if membranes ruptured prematurely. The clinical manifestations vary from mild conjunctival injection with scant watery discharge to severe mucopurulent discharge with eyelid edema, chemosis, and pseudomembrane formation. A 14-day course of systemic erythromycin (50 mg/kg/d, divided in 4 doses). Topical therapy is not indicated.

Neisseria gonorrhoeae: The disease typically presents with profound chemosis, edema of the eyelids, and abundant purulent discharge that might be blood-tinged from superficial hemorrhage within 2 to 5 days of birth; however, it can manifest up to 2 to 3 weeks after delivery. Infants with gonorrheal ON should be hospitalized, treated with frequent irrigation of the conjunctiva and intravenous or intramuscular administration of ceftriaxone (25 to 50 mg/kg, to a maximum dose of 125 mg), and evaluated for disseminated gonococcal disease (eg, arthritis, sepsis, meningitis). Various other bacteria commonly isolated form neonates with conjunctivitis include Staphylococcus, Streptococcus and Haemophilus species.

Care of the eyes: Neonates presenting with signs of conjunctivitis should have a conjunctival swab sent for Gram stain and culture. If Gram-negative diplococci are present on the Gram stain results, the infants and their parents should be treated immediately for presumed gonorrhea. Infants with chlamydial infection should be treated with oral antibiotics. Most of all other forms of bacterial conjunctivitis can be treated with topical antibiotics, with the exception of Pseudomonas infection. Infants should be followed during their treatment and upon completion of therapy to ensure resolution of symptoms.

Prevention: The eyes should be cleaned at birth and once every day using sterile cotton swabs soaked in sterile water or normal saline. Ocular prophylaxis with 1% silver nitrate, 0.5% erythromycin ointment, or 1% tetracycline hydrochloride be given to all newborns, including those born by cesarean section, in the first hour after birth (recommended but not practiced). It is important to note that routine ocular prophylaxis does not prevent chlamydial Ophthalmia Neonatrum. The practice of applying kajal in the eyes is not recommended because it may cause trauma, transmit infections like trachoma or may even cause lead poisoning. If the eyes are sticky they can either be managed by frequent cleaning using sterile cotton swabs soaked in normal saline or by instillation of 10% sulphacetamide eye drops every two to four hours. Some neonates may develop persistent epiphora due to blockage of nasolacrimal duct by epithelial debris. The mother should be advised to massage the nasolacrimal duct area (by massaging the outer side of the nose adjacent to the medial canthus) 5 to 8 times a day, each time before she feeds the baby.
### V. Sclera, Cornea, Pupil, Iris, Fundus

**Outer Circle**

- Look for Blue sclera, growth (Dermoid in goldenhar syndrome)

**Middle Circle**

- a) Large corneas that may appear cloudy.
- b) The pupil — the black center of the eye that normally changes diameter in response to light — is dilated.
- c) The iris (the colored portion of the eye) may show signs of atrophy.
- d) There may also be excessive watering and light sensitivity. *Congenital glaucoma*

**Round shape of Pupil and Iris is distorted: Coloboma**

Large cornea in *congenital glaucoma* compared with normal eye and normal cornea.
Megalocornea a horizontal diameter of >12 mm

Inner Circle

On torch examination - white eye indicates Congenital Cataract

VI. Red reflex

Red reflex either by Ophthalmoscope or Camera: Red reflex is actually seeing the curtain of eye (Retina) which is red. A red glow means the media through which the light has traveled is clear i.e. cornea, lens etc. are not opaque.

Normal red reflex with ordinary Camera

A white glow in a child’s eye could be a sign of eye cancer. See RED or see an eye doctor.

Red reflex

Done for early detection of potentially sight and life-threatening eye disease. Due to the early and time-limited plasticity and development of the eye, any blockage of light to the retina interferes with development of optic neural pathways and can have profound effects on later vision.

Valuable in screening the following conditions:

- Cataracts
- Retinoblastoma
- Vitreous abnormalities
- PHPV, FEVR

Principles of Red Reflex testing

- Assessment is to be done in a dimly lit or dark room.
- It can take 10 seconds from the time the lights go down to the time the pupil reaches maximal dilation.
- Stand 1.5 feet away from the child and look through the direct ophthalmoscope so that the entire face is in clear focus.
- Use a large enough aperture size so that both eyes including the face are illuminated.
- Use different angles to get the red reflex.
- Since the cornea, pupil, anterior chamber, lens, vitreous all are transparent the retina is visible to the examiner. If there is obstruction to the light due to any pathology, it affects the red reflex.

<table>
<thead>
<tr>
<th><img src="image" alt="Ophthalmoscope head" /></th>
<th>Learn the parts of an Ophthalmoscope especially the disc aperture and the wheel to select the strength of a lens</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="White circle of light" /></td>
<td>Get the largest white circle of light by turning the disc of the aperture in the ophthalmoscope as shown:</td>
</tr>
</tbody>
</table>
|                               | - Selection of Aperture Type 
- There are five aperture choices which are changed by turning the Aperture Wheel |

Try without dilating the eyes, If not possible then dilate the eyes

A red reflex examination preceded by pupil dilation with 1% tropicamide or a 1% tropicamide/2.5% phenylephrine mixture administered to each eye approximately 15 minutes before this examination.

| Normal red reflex may be Orange in about 80% and Red in 20% in this part of world. | Children who have an abnormal red reflex (e.g., dark spots, markedly diminished reflex, white reflex, and asymmetry) should be referred to an ophthalmologist |
| In more darkly pigmented children, the reflex may be more gray than red | |

**Normal red Reflex:**
1. Bright
2. Contains no Silhouette
3. Symmetrical in character

**Abnormal red reflex:**
1. Dark spots or other silhouettes
2. Markedly diminished reflex
3. White
### Guidelines for Universal Eye Screening of Newborns

1. **Check for Eyelid Abnormality**
   - **Eye lids may be too narrow**
   - **Hemangioma of eyelid**
   - **Droopy eye lid**
   - **Coloboma of eye lid**

2. **Check for Facial Marks**: (port wine stain or capillary hemangioma)
   - If present, the eyes need careful examination if possible by the local ophthalmologist.

3. **Look for Red Conjunctiva with Eye Discharge**
   - **Red conjunctiva**
   - Eye discharge can be prevented by ocular prophylaxis i.e. cleaning the eyelids and birth, with instillation of antiseptic or antibiotic eye drops or ointment.

4. **Abnormally Small Eye (microphthalmos) or Absent Eye (anophthalmos)**
   - **microphthalmos**
   - **Anophthalmos** – the eye socket is empty with no evidence of eye

5. **Look for Blue Sclera and any, growth on the Sclera**
   - **Dermoid**
   - **Blue sclera**

---

### Recall the Steps: Pictorially

<table>
<thead>
<tr>
<th>Step</th>
<th>Image 1</th>
<th>Image 2</th>
<th>Image 3</th>
<th>Image 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[Image]</td>
<td>[Image]</td>
<td>[Image]</td>
<td>[Image]</td>
</tr>
<tr>
<td>2</td>
<td>[Image]</td>
<td>[Image]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>[Image]</td>
<td>[Image]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>[Image]</td>
<td>[Image]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>[Image]</td>
<td>[Image]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6. Coloboma: A portion of the structure of eye is missing or a gap
   6 a): Eye lid incomplete
   6 b): Pupil round or not (coloboma of iris)

   ![Coloboma of the eye lid](image)
   ![Coloboma of the IRIS](image)

7. Corneal opacity:
   a) Look for Corneal clouding
   b) see for the size of the cornea
   * Corneal clouding with large eyes
   * Corneal clouding with normal size eyes or cornea
   * Congenital cataract
   * Check for photophobia
   * Check for tearing

   ![Megalocornea](image)
   ![Abnormally large eyes, with corneal opacity: Congenital glaucoma in newborn](image)
   ![Corneal opacity without large eyes](image)
   ![Congenital cataract](image)

8. Pupil area: see for any white reflex by using a torch: congenital cataract or vitreous / retinal pathology

   ![White eye](image)

9. See for absence of red/orange glow or any asymmetry in the red glow between the two eyes by using ophthalmoscope

   ![White eye](image)
# SCREENING CUM REFERRAL CARD

<table>
<thead>
<tr>
<th>Name: Baby of</th>
<th>Birth weight: -/-/-/- gm.</th>
<th>Gestational age at time of birth: WW/DD: weeks and days</th>
<th>Estimated day of delivery: mm/dd/yyyy</th>
</tr>
</thead>
</table>

## Any Risk factor

<table>
<thead>
<tr>
<th>Premature birth: at least 21 days before the expected date of delivery</th>
<th>Delayed cry/Birth asphyxia</th>
<th>Has: Down syndrome, Birth asphyxia, hearing impairment or hydrocephalus</th>
<th>Birth defects involving the head or face</th>
<th>Birth weight: if less than 2000 gm.</th>
<th>Admitted in SNCU for &gt; 4 days</th>
<th>Prolonged use of Oxygen &gt;72 hours</th>
<th>Neonatal sepsis</th>
</tr>
</thead>
</table>

Tick if yes √

## Any Family History

<table>
<thead>
<tr>
<th>Family member (blood relatives)</th>
<th>Risk factor:</th>
<th>Family History:</th>
</tr>
</thead>
</table>

1. Retinoblastoma (Congenital Tumor of eye) 8. Nystagmus (roving eye)
2. Severe refractive error, or any visual perceptual problems since child hood 9. Strabismus or crossed eye in other family members
3. Congenital cataract in other family members 10. Albinism in family
4. Congenital Glaucoma in other family members 11. Coloboma or cleft in eyes of other family members
5. Sickle cell disease 12. Retinitis pigmentosa in family
6. Amblyopia (lazy eye) 13. Aniridia
7. Unexplained Vision loss/ or blindness since early childhood 14. Optic atrophy

√ Risk factor: O Family History: O

If yes: ask for follow up even if the initial screen is normal

## VIS ASSESSMENT of New-born eye

### Maternal factors: Suspected of having a congenital infection or diseases during pregnancy?
- e.g., CMV, Toxoplasmosis, Maternal Venereal Conditions, Rubella: Yes/No: Tick if yes

### Facial features: Normal / Abnormal looking: any syndrome identified, any neurological condition identified

### Lids: Normal/swelling/droopy: RL. Conjointiva: Red/Normal R L. |

### Red discharging eyes: Yes/NO (Look for Swelling, excessive watering, or discharge from eyes:)

### Mongolid/ ante mongolid slant/ epicanthic folds: TICK

(Look for Abnormal slant, abnormal folds beneath the eyes (Epicanthic folds), distance between two eyes (more or less than normal), size of the eye opening (smaller than normal)

### Sclera: White/ red inflamed/ any growth: RL |

### Cornea: Transparent/ opaque/unequal both side: RL |

### Large cornea /small cornea |

### Iris: Normal/cleft/abnormal color: RL |

### Pupil: Circular/ clear/white/unequal both side |

Any other abnormality of the eye

<table>
<thead>
<tr>
<th>Pass: If all structures are normal</th>
<th>Rescreen/ Refer: If any abnormality is noted.</th>
</tr>
</thead>
</table>

* If risk factor, the child should be called for rescreening at the DEIC at 3 months.
# Pictorial Tool for Identification of Eye Defects

## 1. Check for Eyelid abnormality

- a. Hemangioma of eye lid
- b. Eye lids may be too narrow
- c. Partially closed eye lid, unable to keep it open Droopy eyelid
- d. Gap in eye lid (coloboma)

## 2. Check for Facial marks (port wine stain or capillary hemangioma)

## 3. Abnormally small eye (Microphthalmos) or Absent eye (Anophthalmos)

## 4. Look for red conjunctiva with eye discharge ophthalmic neonatorum

## 5. Coloboma: A portion of the structure of eye is missing or a gap

## 6. Look for Blue sclera and any growth on the sclera (Dermoid in goldenhar syndrome)

## 7. Pupil area: congenital cataract or vitreous / retinal pathology see for any white reflex by using a torch

## 8. Corneal opacity

- Corneal clouding
- Congenital cataract
- Abnormally large eyes with corneal opacity: congenital glaucoma in newborn
- Corneal opacity without large eyes

## 9. See for absence of red/orange glow or any asymmetry in the red glow between the two eyes by using opthalmoscope

- Red reflex
FOLLOW UP

Mandatory follow up for all “At risk” newborns for vision testing if:

1. Born before 36 weeks or birth weight < 2000 gm.
2. History of family member having poor vision or any eye problem in childhood
3. Family history of any tumor of eye
4. Had any stage of ROP
5. History of not crying at birth or delayed cry after 5 minutes
6. Stay in the SNCU/NICU for more than 4 days
7. Any abnormal looking child or if any syndrome identified, or if any neurological condition identified
8. Any birth defect or congenital abnormalities of other systems or any problem associated with eye
9. Any concern of the parents regarding vision at any time or the medical officer / pediatrician at the time of discharge

* Please mention in the discharge along with the date and venue for the follow up.

**Action required**

<table>
<thead>
<tr>
<th>Eyelid abnormalities</th>
<th>Refer to tertiary eye care services for assessment as surgery may be required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormally small or absent eye(s)</td>
<td>Refer to tertiary eye care services for diagnosis followed by rehabilitation, if both eyes affected</td>
</tr>
<tr>
<td>Congenital glaucoma</td>
<td>Refer to tertiary eye care services for assessment and surgery</td>
</tr>
<tr>
<td>Coloboma</td>
<td>Refer to tertiary eye care services for diagnosis followed by rehabilitation, if both eyes affected</td>
</tr>
<tr>
<td>Corneal opacity</td>
<td>Refer to tertiary eye care services for diagnosis followed by rehabilitation, if both eyes affected</td>
</tr>
</tbody>
</table>

**Abnormal red reflex:**

| Congenital cataract | Refer to tertiary eye care services for assessment and surgery |
| Retinoblastoma | Refer to tertiary eye care services for surgery or other treatment |

The following children are at a higher risk of eye problems:

- family history of congenital cataracts, retinoblastoma, metabolic or genetic diseases
- other congenital abnormalities, such as congenital heart disease
- evidence of intrauterine infection
1. INTRODUCTION

Retinopathy Of Prematurity (ROP) is a retinal disorder of low birth weight premature infants. It can be mild with no visual defects, or it may become aggressive with new vessel formation (neo-vascularisation) and progress to retinal detachment and blindness. The stimulus for the abnormal growth of blood vessels comes from the peripheral immature retina. Nearly one third to half of neonates undergoing screening may show some degree of ROP which fortunately regresses on its own in majority of affected infants, in a few it progresses to the stage of retinal detachment and blindness. Timely screening and treatment of ROP can prevent blindness and minimize visual handicaps.

- Incidence: Studies from India have reported ROP in 20% to 52% of screened neonates. More recent studies reporting lower rates of ROP ranging from 20% to 30%.
- The major risk factor is very low birth weight, prematurity and high oxygen concentration. Associated risk factors are acidosis, apnea, PDA, sepsis, intra-ventricular hemorrhage, and blood transfusion.
- May lead to complete blindness forever, if not screened and treated in time after which even with the best of treatment, no substantial improvement in outcome would occur.

1.1 Objectives of the section

To help the health care providers in clinical decision-making by providing evidence-based information on ROP.

1.2 Clinical questions

The clinical questions for these guidelines are:

a. Who should be screened for ROP?

b. When to screen for ROP?

c. What should be the frequency of screening after the initial examination?

d. How should these babies be screened for ROP?

e. How should they be managed?

f. How to follow up these babies?

1.3 Target population

These guidelines are for the management of infants with the risk of developing ROP and those with the established disease.

1.4 Target group

These guidelines are meant for concerned health care providers based at District hospital, SNCU and DEIC.
# 2. CLASSIFICATION OF ROP: LOCATION/EXTENT/SEVERITY

International Classification of ROP (ICROP) is used for classifying ROP. ROP is categorised based on the severity of the disease into stages (0-5), location of the disease into 3 zones (Zone 1-3), extent of the disease based on clock hours (1-12) and the presence of plus disease.

## 2.1 Classification of ROP (ICROP)

<table>
<thead>
<tr>
<th>Location</th>
<th>Zone 1</th>
<th>Zone 2</th>
<th>Zone 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Circle with optic nerve at its center and a radius of twice the distance from optic nerve to centre of macula (Fovea)</td>
<td>Concentric circle from edge of zone 1 to ora serrata nasally and equator temporally</td>
<td>Lateral crescent from zone 2 to ora serrata temporally</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Severity</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
<th>Stage 5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Presence of thin white demarcation line separating vascular from avascular retina</td>
<td>Addition of depth and width to the demarcation line of stage 1, so as the line becomes ridge</td>
<td>Presence of extra retinal fibro vascular proliferation with abnormal vessels and fibrous tissue extending from ridge to vitreous and the ridge has a velvety appearance with a ragged border</td>
<td>Partial retinal detachment beginning at the ridge where the retina got pulled anteriorly into the vitreous by the fibro vascular ridge not involving macula (4A) and involving macula (4B)</td>
<td>Complete retinal detachment</td>
</tr>
</tbody>
</table>

| Plus disease | Plus disease is an indication of activity and is characterized by the presence of dilatation and tortuosity of retinal vessels at posterior pole of eye. Also associated with pupillary rigidity and vitreous haze. |

| Extent | Extent of ROP described in 30° clock hours (a total of 12 clock hours of 30° each). |

The circumferential extent of the disease is described in segments as if the top of the eye were 12 on the face of a clock for e.g., one reports that there is a stage 1 disease for 3 clock hours i.e., from 4 to 7. The clock hours recorded are the total clock hours involved not just the contiguous sector.
2.2 Disease location

The retina is divided into three concentric circles, each centered on the optic disc.

The retinal vessels grow out from the optic disc to the periphery and the designation of zones corresponds to the vascular developmental pattern.

| Zone 1: Defined by a circle whose radius is twice the distance from the centre of the optic disc to the centre of macula (Fovea). |
| Zone 2: Defined by a circle whose radius is the distance from the centre of the optic disc to the nasal margin of the retina (ora serrata) |
| Zone 3: The remainder of the retina. This is crescent-shaped zone that largely involves temporal retina. |

![Diagram of the retina with zones labeled.](image)
2.3 Disease extent

- Disease extent is recorded as clock hours 1-12 hours or as twelve 30° sectors or 360°
- The clock hours recorded is the total clock hours involved, not just the contiguous sectors.

![Recorded as clock hours 1-12 hours]

2.4 Aggressive posterior ROP (AP-ROP):

A rapidly progressing, severe form of ROP, if untreated, usually progresses rapidly to stage 5 ROP. The characteristic features of this type of ROP include its posterior location, prominence of plus disease, and the ill-defined nature of the retinopathy. This may not have classical ridge or extra retinal fibro vascular proliferation, but rather have innocuous looking retina and tortuous vessels forming arcades. This type of ROP is likely to get missed by inexperienced examiners. Observed most commonly in Zone I, it may also occur in posterior Zone II.

![This is an example of APROP at Zone 1]

2.5 Plus disease

**Plus disease** can be present as a major complicating factor at any stage. It is characterized by:

- Significant level of venous dilation and
- Arteriolar tortuosity of the posterior retinal vessels. This reflects the increase of blood flow through the retina
- Two quadrants of the eye retina must be involved for the changes to be characterized as plus disease.

Associated changes may include

- Iris vascular engorgement
- Poor pupillary dilatation (rigid pupil)
- Vitreous haze and anterior chamber haze
2.6 Pre-plus disease

1. Pre-plus disease indicates posterior pole tortuosity and dilatation that are not sufficiently abnormal to reach the criteria of plus disease, but is nevertheless greater than that regarded as normal.

2. Pre-plus disease may or may not progress to plus disease.
### 2.7 Disease severity (Staging)

- Vascularization of the retina is incomplete or immature prior to the development of ROP.
- Disease severity is determined by staging. More than one stage may be present in the same eye.

<table>
<thead>
<tr>
<th>Stage 1. Demarcation line</th>
<th>● A thin but definite structure separating the avascular retina anteriorly from the posteriorly vascularized retina.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 2. Ridge</td>
<td>● A ridge arising from the demarcation line which has 3 dimensions (height and width) and extends above the retina.</td>
</tr>
</tbody>
</table>
| Stage 3. Extra retinal fibro vascular proliferation | ● Extra retinal fibrovascular proliferation or neovascularization extends into the vitreous from the ridge.  
   ● The posterior aspect of the ridge appears irregular as the proliferation becomes more extensive. |

![Stage 1 ROP (demarcation line)](image1)

![Stage 2 ROP at zone 2 posterior](image2)

![Stage 3 ROP at zone 1](image3)
### Stage 4. Partial retinal detachment

- Retinal detachments are generally concave and most are circumferential.

- They are divided into 2 stages:
  - **4A:** extrafoveal, and
  - **4B:** foveal

### Stage 4A ROP with Nasal Retinal Detachment

### Stage 5. Total retinal detachment

- Retinal detachments are generally tractional but may occasionally be exudative.

- They are usually funnel-shaped.

### Stage 5 ROP.

**Note:** Some ophthalmologists use the terminology “Stage 0” to indicate that no ROP is present.

For the purposes of recording the examination for each eye, the **most severe stage** is documented with the **total extent** of all stages.

- In addition to identifying the zone, stage, and extent of the ROP, there may be other signs to indicate that the ROP is active.
**Plus Disease**

- Plus disease consists of:
  - Increased venous dilatation, and
  - Arteriolar tortuosity of the posterior retinal vessels.
- Associated changes may include:
  - Iris vascular engorgement,
  - Poor pupillary dilatation (rigid pupil), and
  - Vitreous haze.
- Two quadrants of the eye must be involved for the changes to be characterized as plus disease.

**Aggressive, Posterior ROP (AP-ROP)**

a. This is an uncommon, rapidly progressive, and severe form of ROP that has previously been referred to as “Rush disease”. It usually occurs in the smallest, most immature infants.

b. Untreated, it usually progresses to Stage 5 ROP.

c. Characteristic features are:
  - the posterior location,
  - prominence of plus disease, and
  - The ill-defined, mild-appearing, and easily over-looked retinopathy at the junction between the avascular and vascular retina.

d. It is typically circumferential and is often accompanied by a circumferential vessel.

e. It may be difficult to differentiate between arterioles and venules because of significant dilatation of both vessel types.

f. Hemorrhages may be present at the junction between vascularised and avascular retina.

g. It may not progress through the classic stages 1-3 before retinal detachment occurs. It may appear as a flat network of neovascularisation at the junction between vascularised and avascular retina.

h. Indirect ophthalmoscopy using a 20-D condensing lens instead of a 25-D or 28-D lens may assist with determining the presence of the featureless neovascularisation characteristic of AP-ROP.
3. RISK FACTORS FOR ROP

Various risk factors contribute to the development of ROP. They are:

- Prematurity
- Low birth weight
- High exposure to Oxygen for prolong period
- Apnoea
- Sepsis
- Anemia
- Cardiac defects
- Multiple blood transfusion
- Respiratory distress syndrome

**Birth weight and gestational age** – most important risk factors for development of severe ROP

- Infants with very low birth weight are at significantly higher risk of developing severe ROP that requires treatment. Similarly, the severity of ROP is inversely proportional to gestational age. Present evidence shows that low birth weight and gestational age are the most predictive risk factors for the development of ROP.

3.1 Oxygen use

Oxygen therapy has been previously implicated in the aetiology of ROP. The use of supplemental oxygen neither caused progression of pre-threshold ROP nor significantly reduced the number of infants requiring peripheral ablative therapy.

Recent evidence suggests that repeated hypoxic and hyperoxic episodes may be an important factor in the pathogenesis of ROP. Strict management of oxygen delivery without fluctuations and proper monitoring may be associated with decreased occurrence of ROP. Although the exact relationship between oxygen therapy and ROP is currently not well established, oxygen therapy seemed to play an important role in the pathogenesis of ROP.

3.2 Light exposure

- There is no evidence that light exposure is a risk factor in the development of ROP, since reduction in ambient light exposure has not reduced the incidence of ROP in high risks infants.

3.3 Other risk factors

The other risk factors that have been implicated in the development of ROP include anaemia, poor weight gain, blood transfusion, respiratory distress, breathing difficulties and the overall health of the infant. There is active research into the correlation of levels of growth factors in the blood and ROP. Close monitoring has decreased the impact of oxygen use as a risk factor for development of ROP. In addition, ROP has also been associated with intra-ventricular haemorrhage, ante-natal blood loss requiring blood transfusions and surgery under general anaesthesia, sepsis candidemia, carbon dioxide tension, raised serum bilirubin levels, and assisted conception.

- However, there is insufficient evidence to determine the degree of importance of these risk factors in contributing to the pathogenesis of ROP.
Other risk factors of developing ROP include anemia, blood transfusion, sepsis, apnea, hypotension and poor weight gain. In general, other risk factors are surrogate markers of sickness in the baby. Therefore, sicker the baby higher is the risk.

4. SCREENING FOR ROP

4.1 Whom to screen

Screening should be carried out for the infants with either of the following:

1. Birth weight less than 2000 gm
   or
2. Gestational age less than 35 weeks
   or
3. Infants with an unstable clinical course who are at high risk (as determined by the neonatologist or paediatrician)

This ‘third criterion’ is important as it brings in many larger babies into the screening guidelines ambit without raising the screening parameters. The sick new born with: a) cardio-respiratory instability, b) prolonged oxygen therapy, c) repeated episodes of apnoea of prematurity, d) anaemia needing blood transfusion and e) neonatal sepsis or f) believed by their attending paediatrician or neonatologist to be at high risk.

This ‘third criterion’ includes: anemia, blood transfusion, sepsis, apnea, hypotension and poor weight gain. In general, other risk factors are surrogate markers of sickness in the baby. Therefore, sicker the baby higher is the risk. (AIIMs Protocol 2014)

4.2 When to screen

- Should receive first screening at 4 weeks of birth
- Infants weighing less than 1200 grams and period of gestation 24-30 weeks first screening should be done at 2-3 weeks after delivery, and not later than 3 weeks
- The first examination should be done at 4 weeks of post-natal age and not later than 4 weeks

Post Menstrual Age (PMA) in weeks: gestational age plus chronological age.

To calculate first know at what age was he/she born in terms of completed weeks and days. Multiply by 7 to convert into days. Then add total length of stay till date and then divide by 7.

An inborn infant with Gestational Age (GA) of 32 weeks, 3 days, is discharged home from the hospital after 23 days (Initial Length Of Stay (LOS) = 23 days). Note that Initial LOS equals Total LOS for infants who are not transferred.

<table>
<thead>
<tr>
<th>GA Weeks x 7 = 32 x 7 =</th>
<th>224 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>GA Days</td>
<td>+ 3 days</td>
</tr>
<tr>
<td>Total LOS</td>
<td>+ 23 days</td>
</tr>
<tr>
<td></td>
<td>250 days</td>
</tr>
</tbody>
</table>

PMA = 250 / 7 = 35.7 Weeks
Another method is: write the current date: MM/DD/YYYY
Then write the estimated date of delivery: MM/DD/YYYY
Current Gestational age is calculated by:

- Progression of ROP follows a distinct timeline as per Post Menstrual Age (PMA) rather than Post Natal Age (PNA) of the infant.
- **In Indian context**, ROP may be detected even before 32 weeks of PMA. However, ROP usually does not manifest before 2-3 weeks of PNA.
- The median age at detection of stage 1 ROP is 34 weeks.
- Threshold ROP appears at 34 to 38 weeks.
- Vascularization is normally completed by 40 weeks of gestation.

*To simplify, ROP screening should be done at 4 weeks after birth. However, if any baby was delivered earlier than 30 weeks of gestation or birth weight less than 1200 gm should have a ROP screening at 2-3 weeks after birth.*

### 4.3 Duration and frequency of screening

**Initial examination**

- The protocol at the participating center will determine the timing of the initial diagnostic examination.
- In general, the screening examinations will continue **at least every two weeks** until:
  - Vascularization of the retina reaches normal completion, or
  - Until ROP regresses, or
  - Until ROP requiring treatment develops.

### 4.4 Preparation

**Personnel** to carry out screening:

- A team should be constituted consisting of **District Ophthalmologist/Visiting Trained Ophthalmologist** along with **one Doctor** and **one nurse** from the **SNCU** and **Optometrist** from **DEIC**.

- Medical personnel sufficiently trained in ROP screening should perform the examination. Preferably the team should comprise an experienced ophthalmologist, medical officer and a nurse especially of the SNCU. The **ophthalmologist** has to be nominated by district hospital to visit SNCU at least once a week. One **medical officer** and one **nurse** from the **SNCU** have to be made accountable for screening of ROP. The **Optometrist** from the **DEIC** will visit the SNCU daily and would ensure screening and follow up of the at risk children. He/she would further maintain linkages with both the Ophthalmologist and the parents/guardian.

- Integrate ROP screening and management services with **“National Programme For Control of Blindness”** (NPCB).

### 4.5 Place of examination

- Neonates are best examined in the neonatal unit itself under supervision of attending paediatrician/neonatologist. It is not wise to transport small babies to ophthalmic outpatient or ward for examination.
Place should be warm enough and clean. If babies are being screened at an Ophthalmologist’s office, there should be arrangement for basic resuscitation equipment.

- Babies who are admitted at NICU and critically ill should be screened at NICU in presence of neonatologist monitored by pulse oximeter.

4.6 Equipment checklist

Screening can be carried out using the following instruments:

- Indirect ophthalmoscope preferably wireless one
- With a 20, 28 or 30 D lens (28D or 30D lens are usually preferred as they allow easier viewing of the peripheral retina)
- Paediatric speculum (Alfonso speculum)
- Scleral small wire vectis
- Dilator eye drops (a) Tropicamide 0.5% b) Phenylephrine 2.5% (c) Cyclopentolate 0.5%
- Topical anaesthetic eye drop (proparacaine 0.5%)
- Topical antibiotic eye drop e.g. ciplox
- Sterile cotton and gloves
- ROP documentation sheet
- Pamphlets regarding ROP
- Optional: Wide field Digital camera
- Nesting (wrapping) of infants can significantly reduce the stress during screening procedure

Available commercial preparations of Eye drops

- **Tropicacyl Plus Eye drops** (5 ml): Phenylephrine (5%), Tropicamide (0.8%)
- **CYCLOPENT eye drops**: Cyclopentolate 1%.
- **CYCLOPENT PLUS eye drops**: Cyclopentolate 1% & Phenylephrine 5%
- **Sunepherine –Eye drops** (5%): Phenylephrine (5%):

*Tropicamide* is an antimuscarinic drug that produces short acting mydriasis (dilation of the pupil) and cycloplegia when applied as eye drops. It is used to allow better examination of the lens, vitreous humor, and retina. Due to its relatively short duration of effect (4–8 hours), it is typically used during eye examinations such as the dilated fundus examination. Required for new-born 0.5%.

*Cyclopentolate* is a medication commonly used during paediatric eye examinations that dilates the eye (mydriatic), prevents accommodation of the eye to different distances (cycloplegic), and blocks specific receptors called muscarinic receptors (muscarinic antagonist). The drops take around 30–60 minutes to work and usually less than 24 hours to wear off. Required for new-born 0.5% - 1%.

*Sunepherine –Eye (5%): Phenylephrine* (5%): needs to be diluted to 2.5%. Can raise the BP.
4.7. Screening procedure

a) Minimizing risk to the baby

- The examination is done after dilation of the pupils, using lid retractors and scleral depression as needed, and this may increase systemic instability of the baby.

- Special attention should be given to the possibility of bradycardia, arrhythmia, asystole, hypoventilation, apnea, or aspiration.

- Seizures have extremely rarely been reported and feeding intolerance might be present in some babies after the examination, due to the dilating drops.
• Therefore, each baby will be monitored with a member of the NICU staff present during the examination.
• To avoid transmission of conjunctivitis from one baby to another, a separate sterile speculum to be used for each baby after proper handwashing.
• Use of sterile instruments is required for each examination and hand washing or changing of gloves is required between examinations.

b) Infant physiological monitoring
• Before the examination is initiated, the baby will be connected to a pulse oximeter.
• If, at any time during the eye examination, the infant develops significant bradycardia or severe oxygen desaturation, the examination may need to be interrupted until the variables return to the baseline range and the baby recovers.

c) Procedure for the diagnostic eye examination

The examination procedure is as follows:
1. Baby should be well clothed and wrapped. Baby should receive a feed and burped an hour before screening.
2. Pupil should be dilated 30 minutes before examination.
3. Informed consent should be obtained from parents.
4. The baby is swaddled and arms restrained to minimise general movements and an assistant positions the baby for the examination.
5. Topical anesthetic drop proparacaine 0.5% should be applied at conjunctival sac.
6. After instillation of topical anesthesia, a sterile wire lid speculum and scleral indentor for eye rotation may be used. Pediatric speculum should be applied 30 seconds after anesthetic drop.
7. The use of oral sucrose may be considered to help with analgesia.
8. The lid speculum is inserted beneath the lid margins.
9. Screening should be done by an ophthalmologist trained in ROP screening.
d) Examination procedure:

1. First anterior segment examination to be done with condensing lens focusing on cornea, iris and lens to note any media opacity, tunica vasculosa lentis, dilated iris vessels and extent of pupillary dilatation.

2. Retinal examination to be done with indirect ophthalmoscopy using 20D/28D lens. Posterior pole as well as 360 degree peripheral retina should be examined.

3. Sclera depression to be done with wire vectis or specially designed pediatrics depressor if required.

4. Findings to be recorded according to international classification of ROP (ICROP) guidelines. Brief findings to be recorded and provided to parent with clear instruction to adhere strictly to follow up schedule. A pamphlet regarding ROP to be given to all parents.

5. One drop of antibiotic drop to be instilled in each eye at the completion of examination.

6. Baby should be observed for 15 minutes before handing over to parents.

7. Infant with ROP not amenable to laser photo-ablation (stage 4 and stage 5) should be referred to tertiary center for surgical intervention.

e) Recap of the procedure

The following steps are used to determine the status of the eye:

Step 1:

The examining ophthalmologist will examine the posterior pole, and determine the following:

- The presence or absence of plus disease (defined as two or more quadrants of vascular dilation and tortuosity using standard photographs of plus disease for reference).

- If plus disease is not present, the presence or absence of pre-plus disease using standard photographs of pre-plus disease for reference.

Step 2:

The examining ophthalmologist will then examine the remainder of the retina to determine and document the stage, zone and extent of ROP if present.

- Scleral depression is used as needed to visualize the entire fundus out to the ora serrata.

- Particular attention is given to area of scleral indentation, but also adjacent to it to detect peripheral ROP that may be posterior to the downslope of the indentation.

- Each quadrant is examined and the findings are recorded using the ICROP system.

f) Recording the findings in the screening form

- Use of a standardized form using the ICROP zones is encouraged but not mandatory.

  Documentation will include:

  - the zone of vascularisation,
  - the stage of ROP,
● the extent of ROP (in clock hours)
● the presence of plus, or pre-plus, disease,
● the presence of AP-ROP,
● Whether treatment is indicated, and
● When follow-up is planned.

g) Precautions to be taken during screening

● ROP screening examination can have short-term effects on blood pressure, heart rate and respiratory function in the premature baby.

● The examination should be kept as brief as possible and precaution is taken to ensure that emergency situations can be dealt with promptly and effectively.

● Discomfort to the baby should be minimized by administering oral sucrose just before examination.

● Pretreatment of the eyes with a topical proparacaine and swaddling the baby.

● Baby should not be fed just before examination to avoid vomiting and aspiration.

● Hand hygiene should be practiced to maintain asepsis.

h) Dilating regimen: How to dilate?

1. **Tropicamide eye drops**: 0.5% with phenylephrine 2.5% one drop three times at 10 minutes interval.
   Need to dilute commercially available combination dilator (Tropicamide 0.8% with phenylephrine 5%) drop with methyl cellulose eye drops or distilled water. Pupil usually dilates in 30 minutes time and it persists for 30 to 45 minutes.

2. **Cyclopentolate eye drops**: 0.5 to 1%. It will help to keep the pupil dilated longer time specially when Laser is planned.

   **Practice tip**: If pupils are not dilating despite administration of adequate mydriatic drops, severe or advanced ROP should be suspected.

Use of improper eye drop or undiluted eye drop can prove fatal for the baby

● To produce adequate dilation for examination, both cyclopentolate 0.5% and phenylephrine 2.5%, should be employed, one drop to each eye at two different times. (*CYCLOPENT PLUS eye drops*).
   The interval between applications will be 10 minutes.

● In those few babies for whom this dilating regimen proves inadequate, additional 1-2 drops of cyclopentolate 0.5% and 1 drop of phenylephrine 2.5%, can be used for each eye.

● For babies known to have systemic hypertension, the use of phenylephrine should be minimized.

● Topical ophthalmic anesthesia (tetracaine 0.5% or proparacaine) is instilled in both eyes at the discretion of the ophthalmologist.

**Screening of all infants at risk of developing ROP should be continued regularly until**

● Retina is completely vascularised
• ROP has fully regressed and there are no signs of risk for visual loss. This normally happens at around 40-42 weeks of PMA.
• ROP has progressed to a level of severity where treatment is indicated.

The following are the recommended follow up intervals for the infants at risk.

1. **No signs of ROP:**
   
   **Follow up examination for infants at risk should be done 2-3 week intervals until the retina is fully vascularised.**

2. **If ROP is present:**

   **Zone 1:**
   
   Stage 1, 2 or 3; **ROP without plus disease** should be **screened at least weekly** because there is a high risk of disease progression (treatment would be required in plus disease irrespective of the stage i.e., 1, 2 or 3.

   **Zone 2**
   
   1. Immature vasculature should be **screened once in 2-3 weeks.**
   2. Zone 2 stage 1 ROP should be **screened once in 2 weeks.**
   3. Zone 2 stage 2 ROP without plus should be **screened once in 1-2 weeks.**
   4. Zone 2 stage 3 ROP without plus should be **screened at least weekly.**

If there is pre-plus disease, baby should be screened at 3-4 day interval.

<table>
<thead>
<tr>
<th>Zone of retinal findings</th>
<th>Stage</th>
<th>Follow up interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zone 1</td>
<td>Immature vasculature</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td></td>
<td>Stage 1 or 2</td>
<td>1 week or less</td>
</tr>
<tr>
<td></td>
<td>Regressing ROP</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td>Zone 2</td>
<td>Immature vasculature</td>
<td>2-3 weeks</td>
</tr>
<tr>
<td></td>
<td>Stage 1</td>
<td>2 weeks</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>1 week or less</td>
</tr>
<tr>
<td></td>
<td>Regressing ROP</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td>Zone 2</td>
<td>Stage 1 or 2</td>
<td>2-3 weeks</td>
</tr>
<tr>
<td></td>
<td>Regressing ROP</td>
<td>2-3 weeks</td>
</tr>
</tbody>
</table>

5. **MANAGEMENT OF ROP**

The principle of treatment is to remove the stimulus for growth of new blood vessels by ablating the peripheral avascular retina. This will in turn reduce the incidence of retinal detachment and consequent blindness. The treatment involves ablation of peripheral avascular retina and thereby abolishing hypoxic
drive of retina (mediated by over-expression of vascular endothelial growth factor; VEGF). This results in regression of established ROP.

5.1 Timing

When indicated, treatment should be carried out as soon as possible, ideally within 2-3 days of the diagnosis. However treatment is warranted within 48 hours of diagnosis of classical form of disease and as soon as possible in APROP. The rational is that the disease can advance rapidly and any delay in treatment will reduce the chances of success.

5.2 Type of treatment:

1. Laser therapy

Laser therapy is the procedure of choice, being less invasive, less traumatic to the eye and causes less discomfort to the infant Laser is also simpler to apply in treating posteriorly located disease. Both double frequency Nd-YAG laser and Diode red wavelengths laser can be delivered through an indirect ophthalmoscope. Laser burns should be applied on the entire peripheral avascular retina anterior to the ridge, excluding the ridge. Ideally, laser applications should be spaced one half burn-widths apart. Better results were documented with near confluent burn. Additionally, ‘laser spots’ on retina are visible during the procedure minimizing the skip areas requiring re-treatment. The procedure can be carried out under topical anesthesia with or without sedation.

Complications of laser therapy:

Laser treatment may cause burns in cornea and iris. Other complications include cataract, and retinal and vitreous haemorrhage. Ocular ischemic syndrome, angle closure glaucoma, inadvertent damage to the vascularised retina including macula.

2. Cryotherapy

Cryotherapy significantly improves the outcome of severe ROP. This has been largely superseded by laser photocoagulation due to its higher incidence of treatment related complications.

Complications of cryotherapy

Cryotherapy can result in ocular complications like eyelid oedema, laceration of the conjunctiva, and pre-retinal and vitreous haemorrhage as well as systemic complications like bradycardia, cyanosis and respiratory depression.

3. Treatment of advanced disease

Neither cryotherapy nor laser photocoagulation is successful in all cases of advanced disease. Despite meticulous management there may be serious sequelae. Such cases should be referred to centers dealing with advanced retinal surgery.

5.3 Aim of treatment

The aim of treatment is to reduce the incidence of retinal detachment and blindness

The ET-ROP (Early Treatment for ROP) study demonstrated improved visual outcomes with earlier laser treatment and has replaced previous guidelines set by the CRYO-ROP study.
5.4 Indications for both active peripheral retinal ablation and passive waiting for progression/regression

Treatment of ROP is based on differentiation of following two types of ROP:

**Type 1 ROP: Administer peripheral ablation treatment**
- Zone I, any stage ROP with plus disease
- Zone I, stage 3 ROP without plus disease
- Zone II, stage 2 or 3 ROP with plus disease

**Type 2 ROP: Wait and watch for progression/regression**
- Zone I, stage 1 or 2 ROP without plus disease
- Zone II, stage 3 ROP without plus disease

5.5 Laser in ROP

Laser to be done by ophthalmologist trained in ROP laser. It should be performed at SNCU/NICU only in presence of neonatologist with pulse Oximetry monitoring. If required laser can be applied through sloped incubator wall.

5.6 Equipment’s required for laser procedure:
1. Laser console –810 nm diode laser or 532 nm green laser
2. Indirect laser delivery system
3. A pair of laser protective glasses
4. All equipment required for ROP screening

5.7 Indications of laser procedure:
1. Currently laser is the standard treatment for ROP. Laser is to be done according to the ETROP guidelines.
2. Once decided laser is to applied within 48 hours of diagnosis.
3. If the diagnosis is aggressive posterior ROP (APROP) laser is to be done as soon as possible and confluent laser burn to be applied to whole of avascular retina.

5.8 Laser procedure:
1. Informed consent to be taken from parents before the procedure.
2. Oral feeds should be discontinued 1 hour prior to the procedure.
3. Baby should be put on cardio-respiratory monitor and if large area of retina needs to ablated like in Zone I and Zone 2 posterior disease I.V. fluid should be started. Dilatation of pupil is ensured. In addition to tropicamide 0.5% and phenylephrine 2.5%, cyclopentolate 0.5% can be used to have pupillary sustained dilatation for laser photoablation.
4. Can be done under topical anesthesia to avoid systemic side effects of general anesthesia or sedation.
5. 24% dextrose solution can be given orally to minimize the pain during the procedure.
6. If required general anesthesia or sedation can be used.
7. Precaution to be taken to prevent hypothermia, hypoglycemia during and after the procedure.
8. Both the eyes can be treated at the same sitting unless contraindicated by instability of the baby.
9. Vitals to be monitored during and for 2 hours after the procedure.
10. Oral feed to be given 30 minutes after procedure.
11. If baby is not tolerating the procedure, consider abandoning the procedure for the time being. Vital signs and oxygen saturation should be monitored very closely.
12. Premature babies, especially those with chronic lung disease may have increased or re-appearance of apneic episodes or an increase in oxygen requirement. Therefore they should be carefully monitored for 48-72 hours after the procedure.

5.9 Post operative care

Topical antibiotics and steroid to be prescribed three times a day for 7 days. There is increased risk of hyphaema, posterior synechiae and transient cataract in very premature babies specially those with APROP requiring large number of laser burns. Topical mydriatics is also to be added for one week.

5.10 Post operative examination and re-treatment

The purpose of the post operative examination is to determine whether re-treatment is necessary and to monitor the disease regression. After laser therapy first examination to be done 5 to 7 days after treatment and should be continued at least weekly for signs of decreasing activity and regression. Re-treatment should be performed usually 10 to 14 days after initial treatment when there has been a failure of the ROP to regress. Need for long term follow up should be stressed to parents.

_B/O SHAMPA JANA preterm, VLBW (1256 gm), severe birth asphyxia, oxygen for 10 days, sepsis_

_BEST IMAGE_
Stage 3 ROP at Zone 2 posterior with plus disease pre laser

Same eye after laser photoablation

APROP pre laser

APROP POST LASER

APROP pre laser

APROP POST LASER
6. FOLLOW-UP EXAMINATIONS IN SNCU/NICU

6.1 Eyes without ROP

- An immature eye (avascular peripheral retina, no ROP) is examined at least every other week until vessels reach zone III, confirmed by two examinations approximately one week apart or until 44 weeks post-term, whichever occurs first.
- Vascularization has proceeded into zone III when vessels are observed up to the ora serrata in the two nasal clock hours of the eye.
- Examination of this portion of the retina involves scleral indentation with a scleral depressor.
- When normal retinal vasculature progression into zone III has been observed on two occasions at least one week apart, then the baby will be discharged from the ROP protocol and followed according to standard ophthalmological practice.
- There are cases with slowly maturing eyes where the vessels seem never to progress into zone III. If retinal vessels are observed to be in zone II and no ROP has developed on three successive examinations, the time between examinations can be extended while the baby remains hospitalized, and as ophthalmological indicated after discharge.

6.2 Eyes with ROP

- If ROP is observed for the first time and plus disease is not diagnosed, then follow-up examinations will be at least weekly or every other week.
- If ROP is progressing, follow-up examinations will occur at least every other week, but follow-ups will more commonly occur on a weekly or twice-weekly basis depending on the features of the retinopathy.
- If ROP is observed by the ophthalmologist to be regressing on two successive examinations, follow-up will be as indicated by the examining ophthalmologist.
- If the examining ophthalmologist determines that ROP warranting treatment is present, treatment will be delivered according to standard clinical care.

7. COMPLICATIONS OF ROP

- Myopia occurs in about 80% of infants with ROP.
- Strabismus and amblyopia are also common residual findings. The prevalence of strabismus ranges from 23% to 47% in infants with ROP and found to be 20% in a regional study.
- Retinal detachment has been seen in 22% patients. Retinal detachment can occur as early as 6 months up to 31 years from the time of diagnosis, with a mean age of 13 years in regressed ROP patients.
- Retinal detachment may even occur in sub-threshold ROP.
- Acute angle closure glaucoma can be seen in cicatrical ROP.

8. ISSUES, FOLLOW UP AND COUNSELLING

8.1 Post screening

- Assessment of vision should be carried out in all pre-term infants throughout the first year of life to detect associated disorders like neurological abnormalities and amblyopia.
• Periodic monitoring of visual acuity is also carried out since severe ROP may be associated with impaired visual development.

8.2 Children treated for ROP

Post treatment follow-up should be carried out for all infants till they reach pre-school years, to monitor the development of vision, refractive status and strabismus.

8.3 Children with APROP

• Follow-up examinations should be tailored individually.
• If adequate laser/cryotherapy treatment has been given, and the disease has fully regressed, a follow-up examination should be carried out at 3 months.
• Cycloplegic refraction should be performed at 6 months.
• Follow-up should be annually. Sometimes more frequent follow up is necessary if indicated.

8.4 Children with complications of ROP

Ophthalmologist must ensure that the child gains early access to the services for the visually impaired. The social and educational services provide much needed support to these children.

8.5 Counselling

Counselling of the parents is essential depending on the severity of the disease

• **Parents of all babies at risk** - written general information should be provided
• **Parents of infants with severe ROP** - the ophthalmologist should personally discuss about the disease and availability of management with the parents.
• **Parents of infants with advanced cicatricial ROP and with visual impairment** – It is important to ensure that children with visual impairment have access to all services, registration with relevant associations of the blind and vocational guidance centers.

9. OTHER MODALITIES OF TREATMENT

Bevacizumab

• Intravitreal injection of bevacizumab, a neutralizing anti-VEGF molecule has been demonstrated to diminish the neovascular response significantly in animal models and human studies.
• Intravitreal injection of bevacizumab (Avastin) has been reported as a supportive measure in aggressive posterior retinopathy of prematurity.
• In a 2011 clinical trial comparing bevacizumab with conventional laser therapy, intravitreal bevacizumab monotherapy showed a significant benefit for zone I but not zone II disease when used to treat infants with stage 3+ retinopathy of prematurity.
• Potential benefits of intravitreal Avastin injection over laser therapy include: reduction in level of anesthesia required, preservation of viable peripheral retina, and, possibly, reduced incidence of subsequent high refractive error.
• However, the safety of this new treatment has not yet been established in terms of ocular complications as well as systemic complications. The latter are theoretically possible, as the active ingredient of bevacizumab not only blocks the development of abnormal blood vessels in the eye but may also prevent the normal development of other tissues such as the lung and kidney.

• As VEGF is an important mediator of lung growth and brain development, and there is significant systemic absorption of anti VEGF mediation after intravitreal injection, there are concerns regarding toxicity of such therapy.

• Due to lack of data on potentially serious systemic adverse effects administration of intravitreal bevacizumab (anti-VEGF monoclonal antibody) is not routinely recommended in neonates with ROP.

• It may be used only when laser photocoagulation fails and after taking informed consent from the parents.

• Zone I ROP where even there center of macula is not vascularised, ROP not regressing despite adequate laser as a pre-operative measure in Retinal detachment with high vascularity to reduce intra operative bleeding.

Use of wide-field digital camera (Ret-Cam) for screening:

A wide-field digital camera (Ret-Cam) capable of retinal imaging in preterm infants has been evaluated as an alternative to Indirect Ophthalmoscope for screening. Retinal images taken by camera can be stored, transmitted to expert, reviewed, analyzed and sequentially compared over time and are useful for telemedicine purposes. However, due to high cost and limitations in diagnostic accuracy particularly with poor image quality, Ret-Cam cannot replace Indirect Ophthalmoscope in current scenario. Digital fundus images acquired by Ret-Cam can serve as a useful adjunct to conventional bedside ROP screening by Indirect Ophthalmoscope.

Regional shortages in the availability of ophthalmologists to provide ROP diagnostic examinations are an important barrier to ensuring appropriate ROP care.

One potential solution is to decrease the number of indirect ophthalmoscopy examinations by first screening with some other method.

Digital retinal cameras that can be used in the NICU are now commercially available. In general, they can be categorized as wide-angle cameras (e.g., RetCam [Clarity Medical Systems, Inc., Pleasanton, CA]) and narrow-angle cameras (e.g., NM-200D [NIDEK, Inc., Fremont, CA]). Wide-angle cameras provide a greater view of the retina (e.g., 130° field of view) than narrow-angle cameras (e.g., 30° field of view).

However, compared with narrow-angle cameras, wide-angle cameras are currently more expensive and less portable and require that the camera lens be in direct contact with the cornea.

Both types of cameras can produce digital images that could be transferred remotely for evaluation. Computer-assisted algorithms have been developed to assist with the interpretation of the images.

Until the evidence base for digital imaging improves, we do not recommend that those NICUs/SNCU with access to ophthalmologists experienced in ROP transition to use of retinal imaging to detect eyes with ROP.

NICUs/SNCU with poor access to experienced ophthalmologists should first attempt to improve such access by working with the local ophthalmologic community and hospital administration before adopting retinal imaging. Finally, we strongly recommend that all NICUs/SNCU that elect to adopt retinal imaging collect outcome data to expand the evidence base and monitor for any cases of potentially preventable visual impairment.
The key questions for Retinal imaging for SNCU are mainly the costs and benefits of using retinal imaging to detect ROP, Linking up with management for ROP, maintenance of the equipment and finally any risk associated with Retinal Camera. Till then in India: binocular indirect ophthalmoscopy examinations are recommended for infants at risk for the development of ROP Serial diagnostic examinations are performed until each eye is considered no longer at risk for developing serious ROP (i.e., full retinal vascularization, postmenstrual age of 45 weeks, and no pre-threshold disease, zone III retinal vascularization without previous zone I or II ROP, or regression of ROP).

RETCAM SHUTTLE
WIDE FIELD DIGITAL IMAGING SYSTEM With all standard accessories
# 10. ROP RECORDING FORM

## Neonatal Ophthalmology Examination Record for ROP

<table>
<thead>
<tr>
<th>Identification</th>
<th>Name: Baby of</th>
<th>Date of birth</th>
<th>Birth weight</th>
<th>Gestational age at time of birth</th>
<th>Estimated day of delivery (by LMP/USG)</th>
<th>SNCU Data base:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxygen supplementation Y/N: □□ □□ hrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sepsis Y/N. Clinical/screening proven/culture proven</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood transfusion Y/N No of unit □□</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple births Y/Order □□</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEC. Y/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apnea. Y/N: no of episodes □□</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RDS. Y/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia Y/N: Hb g% □□</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombocytopenia Y/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intra-ventricular hemorrhage Y/N, grade □</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular defect other than PDA Y/N.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDA Y/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>maternal factor – H/o hypertension/anemia/assisted conception/premature rupture of AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Name of the Hospital

<table>
<thead>
<tr>
<th>Current Date: MM/DD/YYYY</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDD: MM/DD/YYYY (40 w)</td>
</tr>
<tr>
<td>Current Gestational Age: Weeks and days</td>
</tr>
<tr>
<td>Follow Up No.:</td>
</tr>
<tr>
<td>Any Comments On: Cornea, Iris, lens, Pupil, Vitreous, optic nerve</td>
</tr>
</tbody>
</table>

## Report

<table>
<thead>
<tr>
<th>Zone: 1-3</th>
<th>Stage: 1-5</th>
<th>Preplus: Y/N</th>
<th>Plus Disease: Y/N</th>
<th>Total Clock hours</th>
<th>APROP Y/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>any other ocular abnormality detected</td>
<td>1. Lids:</td>
<td>2. Conjunctiva:</td>
<td>3. Cornea:</td>
<td>4. Iris:</td>
<td></td>
</tr>
</tbody>
</table>

## Recommendation

Follow Up/Laser ablation/referral to tertiary center for surgical intervention

Next follow up date: MM/DD/YYYY
Follow Up Form

<table>
<thead>
<tr>
<th>Name of the Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Date</strong>: MM/DD/YYYY</td>
</tr>
<tr>
<td><strong>EDD</strong>: MM/DD/YYYY (40 w)</td>
</tr>
<tr>
<td><strong>Current Gestational Age</strong>: Weeks and days</td>
</tr>
<tr>
<td><strong>Follow Up No.</strong></td>
</tr>
<tr>
<td><strong>Any Comments On</strong>: Cornea, Iris, lens, Pupil, Vitreous, optic nerve</td>
</tr>
</tbody>
</table>

### Report

<table>
<thead>
<tr>
<th>Zone: 1-3</th>
<th>Stage: 1-5</th>
<th>Preplus: Y/N</th>
<th>Plus Disease: Y/N</th>
<th>Total Clock hours</th>
<th>APROP Y/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>any other ocular abnormality detected</td>
<td>1. Lids:</td>
<td>2. Conjunctiva:</td>
<td>3. Cornea:</td>
<td>4. Iris:</td>
<td></td>
</tr>
</tbody>
</table>

### Recommendation

| Follow Up /Laser ablation/ referral to tertiary center for surgical intervention | Next follow up date: MM/DD/YYYY |

### 11. PREVENTIVE MEASURES

**Antenatal steroids**

Use of prenatal steroids is a well-known approach to prevent respiratory distress and intraventricular hemorrhage, two important risk factors of ROP. Though antenatal steroids have not reduced occurrence of ROP, perhaps because it saves smaller babies who are at higher risk of developing ROP, but, as it reduces sickness level in preterm infants, prenatal steroids are likely to reduce severe ROP.

**Judicious oxygen therapy**

Oxygen is a drug and it should be used judiciously. Each neonatal unit should have a written policy regarding when and how to use oxygen and target saturations.
If a preterm neonate <32 weeks gestation needs resuscitation at birth, inhaled oxygen concentration (FiO₂) should be titrated to prevent hyperoxia and achieve gradual increase in oxygen saturation (70% at 3 minute and 80% at 5 minute after birth). During acute care of a sick preterm neonate, ROP is more likely to develop if partial pressure of oxygen in arterial blood is more than 80 mm Hg.

**Oxygen level in blood should be continuously monitored using pulse oximetry keeping a saturation target of 90% to 93%, with limits set at 88% and 95%. It has been observed that if oxygen saturation in a baby on oxygen therapy is kept between 85% and 93%, in about 90% samples partial pressure of oxygen is in desirable range (50 to 80 mm Hg).** It is important that a work culture is inculcated wherein physicians and nurses respond to monitor alarms.

Therefore it is recommended that saturations in preterm neonates be maintained between 90% and 95%. Saturations should be monitored in preterm infants receiving oxygen therapy to prevent hyperoxia or hypoxia.

**Judicious use of blood transfusions**

Transfusion of packed RBCs is another risk factor of ROP. Adult RBCs are rich in 2, 3 DPG and adult. Hb binds less firmly to oxygen, thus releasing more oxygen to the retinal tissue.

**Packed cell transfusions should** be given when hematocrit falls below following ranges:

- Ventilated infants: 40%
- Infants with cardio-pulmonary disease but not on ventilators: 35%
- Sick infants but no cardiopulmonary instability: 30%,
- Symptomatic anemia (tachycardia >180/minute or respiratory rate > 60 for ≥ 24hour, doubling of the oxygen requirement in last 48 hours, lactate > 2.5 mEq/L or acute metabolic acidosis with pH <7.20 or weight gain less than 10 grams/kg/day over 4 days while receiving 120 kcal/kg/day): 25%
- Asymptomatic anemia: 20%.

**Other interventions**

Supplementation of high doses of Vitamin E or reduced ambient light exposure is not associated with reduced incidence of ROP. In neonates with early stages of ROP administration of supplementation oxygen to achieve oxygen saturation in supra-physiological range and to reduce retinal hypoxia is not associated with halt in progression of ROP.

**12. QUALITY IMPROVEMENT**

**Protocol based approach**

- All units caring for babies at risk of ROP should have a written protocol in relation to the screening for, and treatment of, ROP. This should include responsibilities for follow-up of babies transferred or discharged from the unit before screening is complete.
- If babies are transferred either before ROP screening is initiated or when it has been started but not completed, it is the responsibility of the consultant neonatologist to ensure that the neonatal team in the receiving unit is aware of the need to start or continue ROP screening.
• Whenever possible ROP screening should be completed prior to discharge. There should be a record of all babies who require review and the arrangements for their follow-up.
• For babies discharged home before screening is complete, the first follow-up out-patient appointment must be made before hospital discharge and the importance of attendance explained to the parents.

Auditing

Following outcomes should be regularly audited in units with ROP screening and treatment programme.
• Completeness of screening program: Percentage of eligible babies who receive at least one ROP eye examination.
• Timing of first screen: Percentage of eligible babies receiving first ROP screening exam by 4 weeks of postnatal age.
• Timing of treatment: Percentage of babies needing ROP treatment for their ROP who are treated within 48 hours of the decision to treat being made.

13. STRATEGIES FOR CONTROL OF VISUAL LOSS FROM ROP

<table>
<thead>
<tr>
<th>PRIMARY PREVENTION</th>
<th>SECONDARY PREVENTION</th>
<th>TERTIARY PREVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Prevention of preterm birth</td>
<td>* Early detection of sight threatening ROP</td>
<td>* Surgery for retinal detachment due to ROP</td>
</tr>
<tr>
<td>* In situ transfer with preterm delivery in health facility with SNCU/NICU</td>
<td>* Urgent treatment of sight threatening ROP</td>
<td></td>
</tr>
<tr>
<td>* Antenatal steroids for threatening preterm delivery</td>
<td>* Follow up of treated infants</td>
<td></td>
</tr>
<tr>
<td>* Prevention of ROP among preterm infants by high quality neonatal care from immediately after delivery and in the SNCU/NICU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the delivery room</td>
<td>In the SNCU/NICU</td>
<td></td>
</tr>
<tr>
<td>* Gentle resuscitation in room air</td>
<td>* Avoid 100% unmonitored supplemental oxygen</td>
<td></td>
</tr>
<tr>
<td>* Avoid ventilation</td>
<td>* Prevent sepsis by hand washing</td>
<td></td>
</tr>
<tr>
<td>* Avoid 100% supplemental oxygen</td>
<td>* Promote feeding with breast milk</td>
<td></td>
</tr>
<tr>
<td>* Delayed cord clamping</td>
<td>* Avoid unnecessary blood transfusions</td>
<td></td>
</tr>
<tr>
<td>* Maintain body temperature</td>
<td>* Supportive care, including swaddling and kangaroo care</td>
<td></td>
</tr>
</tbody>
</table>

Note: Primary prevention of sight threatening ROP should be emphasised in the Facility Based Newborn Care Guidelines used by SNCUs.
14. EXERCISE ON ROP

For each of the image of affected eyes due to ROP, you will need to complete the details of the examination of the eye:

- Zone of vascularisation
- Stage of disease
- Presence of plus or pre-plus disease
- Presence of APROP
- Whether treatment is indicated
- The final image will allow you to assess the extent

Take help from these figures

<table>
<thead>
<tr>
<th>Image</th>
<th>Zone</th>
<th>Stage</th>
<th>Plus disease</th>
<th>APROP</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image 1" /></td>
<td>Zone:</td>
<td>Stage:</td>
<td>Plus disease:</td>
<td>APROP:</td>
<td>Treatment:</td>
</tr>
<tr>
<td><img src="image2.png" alt="Image 2" /></td>
<td>Zone:</td>
<td>Stage:</td>
<td>Plus disease:</td>
<td>APROP:</td>
<td>Treatment:</td>
</tr>
<tr>
<td>Zone:</td>
<td>Stage:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plus disease:</td>
<td>APROP:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zone:</th>
<th>Stage:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plus disease:</td>
<td>APROP:</td>
</tr>
<tr>
<td></td>
<td>treatment:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zone:</th>
<th>Stage:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plus disease:</td>
<td>APROP:</td>
</tr>
<tr>
<td></td>
<td>treatment:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Zone:</th>
<th>Stage:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plus disease:</td>
<td>APROP:</td>
</tr>
<tr>
<td></td>
<td>treatment:</td>
</tr>
<tr>
<td><strong>Zone:</strong></td>
<td>..................................................................</td>
</tr>
<tr>
<td><strong>Stage:</strong></td>
<td>..................................................................</td>
</tr>
</tbody>
</table>
| **Plus disease:** | .......................................................
| **APROP:** | ...........................................................

This fundal image shows a clear demarcation line consistent with Stage 1 ROP. The vascularity extends into Zone II. On this image, the ROP is seen to extend for at least 4 clock hours from 7 o’clock to 11 o’clock. There is no evidence of plus disease or pre-plus disease. There is no evidence of AP-ROP. No treatment is indicated. It is recommended that the infant is reviewed in 2 weeks.

This image demonstrates Stage 2 ROP in Zone II. A clear ridge is seen at the border of the vascularised and avascular retina. On this image, the ROP is seen to extend for at least 3 clock hours from 1 o’clock to 4 o’clock. There is mildly increased tortuosity of vessels, indicating the presence of pre-plus disease. There is no evidence of AP-ROP. No treatment is indicated. It is recommended that the infant is reviewed in 1 week.

This image demonstrates Stage 3 ROP in Zone II. A clear ridge is seen at the border of the vascularised and avascular retina. There is extraretinal fibrovascular proliferation extending into the vitreous from the ridge. The posterior aspect of the ridge is irregular. On this image, the ROP is seen to extend for at least 4 clock hours from 1 o’clock to 5 o’clock. There is evidence of pre-plus disease. There is no evidence of AP-ROP. Treatment is not indicated. Follow-up is recommended in one week.

This image demonstrates Stage 3 ROP in Zone II. On this image, the ROP is seen to extend for at least 4 clock hours from 7 o’clock to 11 o’clock. There is marginally increased tortuosity of vessels, indicating the presence of pre-plus disease. There is no evidence of APROP. Treatment is not indicated. Follow-up in one week is recommended.
<table>
<thead>
<tr>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td>This image demonstrates Stage 3 ROP in Zone I. On this image, the ROP is seen to extend for at least 4 clock hours from 7 o'clock to 11 o'clock. Plus disease is present. There is no evidence of APROP. Treatment is indicated.</td>
</tr>
<tr>
<td><img src="image2.png" alt="Image" /></td>
<td>This image demonstrates Aggressive Posterior ROP in the posterior pole. Prominent “seafan”-shaped circumferential neovascularisation is present between Zones I and II. AP-ROP is difficult to stage as it does not follow the usual progression. There is marked tortuosity of the vessels. There are vitreous haemorrhages seen in at the junction of the vascular and avascular retina. There is also vitreous haze. The findings are indicative of Aggressive Posterior ROP. Treatment is indicated.</td>
</tr>
</tbody>
</table>

**Photo Courtesy:** Dr. Pranab Das, Calcutta Medical Research Institute

[http://www.boostnz.info/ROP/imagereview1.htm](http://www.boostnz.info/ROP/imagereview1.htm)
STEPS INVOLVED IN IMPLEMENTING UNIVERSAL EYE SCREENING IN NEWBORNS INCLUDING ROP

A. Basic Steps

- **Universal Vision Screening** should be done at all delivery point through Doctors & ANMs/Staff Nurses.
- All States and UTs should establish at least one State level Apex unit for ROP which would function also as a training unit. This unit should be located at the SNCU/NICU of a Government Institution.
- Instruments like Indirect Ophthalmoscope, dedicated LASER equipment with indirect console should be placed at this unit. RETCAM can be optional.
- Both the screening and management should be done at the SNCU/NICU. At least 2 beds to be reserved for ROP procedure and a dedicated radiant warmer to be earmarked for the same.
- One doctor and one nurse from SNCU/NICU to be assigned and trained for screening & management of ROP.
- Ophthalmologist to be identified either within the Gov. sector or even from any private sector who could visit at least twice a week and could be paid for each case as per the norms.
- Help from collaborative centres to be sought in establishing teaching & training units.

B. Service Mapping (Desk Work)

Baseline Service and resource mapping should be done to prioritize ROP services provision in the SNCU units in phased manner.

- **SNCUs in Medical Colleges and District Hospitals:**
  - Assess the number of infants ≤2000gm admitted who survive to discharge so as to prioritize ROP program implementation in SNCUs caring for the largest number at risk in the first instance (Government database)
- **Eye care providers:**
  - Ophthalmologists in Regional Institutes of Ophthalmology, Medical Colleges and District Hospitals and their existing skills/willingness to be trained in a) screening and b) treating ROP
  - Ophthalmologists in the private sector and their competencies in screening and treatment
  - Equipment available for screening and treating ROP
- **District Early Intervention Centers (DEICs) -** location, staffing levels and equipment for eye care (as per the RBSK Guidelines)
  - Prioritize a functioning SNCU within the state with adequate load and upgrade it as the nodal center for teaching and training of SNCU staff and district Ophthalmologist.
  - Collaborative institutions including Medical College could be used for mentoring such state-wise nodal training center
### Formation of a committee at the district level comprising:

1. Chief Medical officer
2. Nodal officer RCH
3. Ophthalmologist of the District Hospital
4. Medical Officer of SNCU
5. Nursing Staff of SNCU
6. Optometrist from the DEIC
7. Administrative personnel of the District Hospital
8. Representation from NPCB
9. Representation from Local Ophthalmic association
10. DEIC Manager

### Ensure:

**ROP Screening for all preterm in accordance with the guidelines for Screening and management of ROP under RBSK**

- a. all preterm infants admitted to SNCU weighing less than or equal to 2000 gm. at birth
- b. all preterm infants weighing more than 2000 gm. who have received supplemental oxygen or have suffered from sepsis
- c. if the SNCU Paediatrician has any concern

### Ensure:

- a. The nursing staff line-list all the babies fulfilling the criteria for ROP
- b. that the pupils are dilated half an hour before the ophthalmologist comes for screening
- c. SNCU Doctor has counselled and taken the consent from the family
- d. the screening sets and instruments are sterile and ready
- e. the optometrist and nurse assist the ophthalmologist in the screening

### Ensure:

- a. That the DEIC Manager and the optometrist have maintained the record
- b. Counselling and Follow up with the parents

### Ensure:

- That the indirect ophthalmoscope is available along with the 20 D lens
- Training has been imparted to both the ophthalmologist and optometrist in this aspect

### Ensure:

- Superintendent of the District Hospital to help in the logistics including availability of funds to support this activity

### Ensure:

- Superintendent of the District Hospital to make this mandatory
- DEIC Manager to see that the optometrist regularly visits the SNCU
### Ensure: Follow-up:

1) Every pre-term is followed up till either the retinal vessels become mature or the ROP regresses and the PMA is greater than 42 weeks. 
2) Parents understand the significance of this follow up and if need be urgent treatment / assessment is made possible.

### Ensure:

**SNCU in charge** follows the protocol for new born vision examination and ROP for preterm. That the DEIC Manager should maintain monthly records of all such children along with their follow up and ensure that the data is reflected in the SNCU Data Base.

### Level Roles and responsibilities

<table>
<thead>
<tr>
<th>Level</th>
<th>Roles and Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td><strong>MoHFW</strong></td>
</tr>
<tr>
<td></td>
<td>* Integrate universal eye screening including ROP screening and treatment services with NPCB and RBSK</td>
</tr>
<tr>
<td></td>
<td>* Integrate ROP prevention and screening data fields in the online SNCU and RBSK database</td>
</tr>
<tr>
<td></td>
<td>* Integrate ROP service with guidance of National Collaborative Centre for SNCU.</td>
</tr>
<tr>
<td></td>
<td><strong>AIOS and Vision 2020</strong></td>
</tr>
<tr>
<td></td>
<td>* Increase awareness and participation of VR specialist in ROP screening and treatment.</td>
</tr>
<tr>
<td></td>
<td>* Making parents aware of the important causes of childhood blindness and its prevention; importance of universal eye screening and ROP screening</td>
</tr>
<tr>
<td>Regional</td>
<td>* Centers of Excellence for neonatal care and eye care will provide technical support in capacity building and mentoring.</td>
</tr>
<tr>
<td></td>
<td>* Establish pool of trainers for screening and management of ROP</td>
</tr>
<tr>
<td></td>
<td>* Identify one Medical College/ Hospital to support 2-3 Nodal SNCUs.</td>
</tr>
<tr>
<td>State</td>
<td>* Identify one nodal SNCU for operationalization of ROP and Universal Eye Screening at all the District SNCUs</td>
</tr>
<tr>
<td></td>
<td>* Ophthalmology department to train ophthalmologists, PGs and DH ophthalmologist. Pediatrics department to train SNCU staffs and doctors</td>
</tr>
<tr>
<td></td>
<td>* Collaborate with State chapters of professional bodies</td>
</tr>
<tr>
<td>District</td>
<td>* District coordinator has to report the current statistics to State.</td>
</tr>
<tr>
<td></td>
<td>* District coordinator has to provide list of potential trainees.</td>
</tr>
<tr>
<td></td>
<td>* DEICs to screen for other visual impairments and refer to pediatric ophthalmologist</td>
</tr>
<tr>
<td>Facility# (see below)</td>
<td>* Delivering screening services with appropriate referrals</td>
</tr>
<tr>
<td></td>
<td>* Recording and reporting information on screening and treatment</td>
</tr>
<tr>
<td></td>
<td>* Arrange long term follow up of all preterm infants at DEIC</td>
</tr>
<tr>
<td>Community</td>
<td>* ANMs and ASHA workers generate awareness and promote antenatal steroids and facility based deliveries</td>
</tr>
<tr>
<td></td>
<td>* Ensure follow up for screening and long term follow up</td>
</tr>
</tbody>
</table>
### Roles and Responsibilities of SNCU staff

<table>
<thead>
<tr>
<th>Neonatologist/ Pediatrician</th>
<th>SNCU Nurse for ROP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Identify infants to be screened</td>
<td>1. Keep a diary of the date for screening of all at risk infants from the date of admission and thereafter in coordination with neonatologist</td>
</tr>
<tr>
<td>2. Perform Universal Eye Screening including Red Reflex</td>
<td>2. Perform Universal Eye Screening</td>
</tr>
<tr>
<td>3. Document findings of each baby screened</td>
<td>3. Prepare equipment and child for screening</td>
</tr>
<tr>
<td>5. Ensure receiving neonatal unit of infant referred to another neonatal unit are informed of the need for further screening, if required</td>
<td>5. Ensure findings and management decisions are documented</td>
</tr>
<tr>
<td>6. Communicate with and counsel parents about the need for further screening, and when</td>
<td>6. Communicate with and counsel parents about the need for further screening, and when</td>
</tr>
<tr>
<td>7. Report the statistics to the district coordinator on a monthly basis</td>
<td>7. Report the statistics to the district coordinator on a monthly basis</td>
</tr>
<tr>
<td>8. Provide ANMs and ASHAs information about the infant which needs follow up</td>
<td>8. Provide ANMs and ASHAs information about the infant which needs follow up</td>
</tr>
</tbody>
</table>

### Roles and Responsibilities of DEIC staff:

- The optometrist has to daily visit the SNCU
- Examine all children within the SNCU for Vision: including Red reflex, torch light for pupillary examination and visible Eye defects
- Be part of the team along with the SNCU staff to screen ROP for preterm children
- Along with DEIC manager help in follow up and documentation
# INTEGRATED APPROACH TO UNIVERSAL EYE SCREENING

<table>
<thead>
<tr>
<th>DEPARTMENT OF NHM CHILD HEALTH</th>
<th>NATIONAL PROGRAM FOR THE CONTROL OF BLINDNESS (NPCB)</th>
<th>RBSK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PREVENTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Ensure identification of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>all preventable causes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>of childhood blindness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Promote facility based</td>
<td></td>
<td></td>
</tr>
<tr>
<td>delivery of preterm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>babies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Ensure antenatal steroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for mothers likely to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>deliver preterm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Ensure high quality care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>practices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Ensure availability of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>essential equipment and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infrastructure</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCREENING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Set-up screening protocols in all delivery points for universal eye screening in newborns</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Set-up screening protocols in SNCUs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Identify infants to be screened as per guidelines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Ensure competent screeners visit on a regular weekly basis and document their findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TREATMENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coordinate with treating</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ophthalmologist and provide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>support during and after</td>
<td></td>
<td></td>
</tr>
<tr>
<td>laser treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FOLLOW UP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine follow up of all preterm infant until the age of 2 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCREENING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure participation of District Hospital ophthalmologists in competency based management of universal eye screening including ROP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TREATMENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure all centres with trained ophthalmologists have equipment for screening and laser treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FOLLOW UP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine follow up of all infants treated for sight threatening ROP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCREENING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNCU neonatologists/pediatricians ensure all infants admitted are screened for eye disorders including ROP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TREATMENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skilled ophthalmologists conduct laser/surgery according to need</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FOLLOW UP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine follow up of all preterm infant until the age of 7 years for other visually impairing complications</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Flow chart: Roles and responsibilities at each level

National Level
- MoHFW
- NNF
- AIOS and VISION 2020 India

Regional/Zonal Level
- Mentoring eye institutions
- Mentoring neonatal institutions

State Level
- Child Health
- Government Medical College
- Director of Medical Education
- Blindness control programme
- RBSK

District Level
- District Hospital
- DEIC

Facility Level
- SNCU personnel

Community Level
- ANMs and ASHA

Less childhood blindness from ROP
Flowchart depicting activities to be undertaken at each level

**National ROP Task Force** → **National Health Mission**

**Regional Institutes of Ophthalmology, Medical Colleges; District Eye Units**
- Ophthalmologists; optometrists

**National Program for Blindness Control**
- Technical support

**Maternal Child Health**
- Child Health
  - Ownership and leadership

**RBSK**
- Coordination and financial support

**District Early Intervention**
- Coordination and financial support

**Primary Health Centres**

**Facilities**

**Activities in relation to ROP**
- Screening in NICU/reading images
- Treatment in NICU
- Follow up after treatment
- Prevent ROP
- Identify infants at risk of ROP
- Support screening and treatment
- Provide equipment to screen and treat ROP at SNCU/District Eye Units
- Long term follow up of all preterm infants, with visual acuity testing
- Referral to eye care, if required
- Rehabilitation/referral for education assessment, if required

**Village**

**Community**

**Health Sub Centres**
- ANMs x1-2
  - ASHA Workers x4-5

**Encourage facility based delivery of women in preterm labour**
**Educate and support mothers of preterm infants who require further ROP screening after discharge**
**Educate and support mothers of preterm infants to attend Early Intervention Centres for assessment**
### Roles and responsibilities of the neonatology team and ophthalmologist (or technician) in relation to screening for ROP in the SNCU

<table>
<thead>
<tr>
<th>Roles</th>
<th>Guidelines</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identify infants to be examined/screened</td>
<td>Use national guidelines</td>
<td>Neonatologist</td>
</tr>
</tbody>
</table>
| Document date of first examination / screening in medical/nursing records | Use ROP diary | ROP nurse  
Neonatologist |
| Communicate need for examination/screening to parents | Verbal explanation and written information | ROP nurse  
Neonatologist |
| Prepare infants for examination | Use national guidelines | ROP nurse |
| Assist ophthalmologist/ technician during examination | | ROP nurse |
| Monitor infant during examination/screening | | ROP nurse |
| Document findings | Medical records  
Nursing records | Ophthalmologist  
ROP nurse |
| Communicate findings to parents | | ROP nurse |
| Inform parents if further exam is needed and when | | Ophthalmologist  
ROP nurse |
| Document date for next exam in medical/nursing records | Use ROP diary  
In medical records/discharge summary | Ophthalmologist  
ROP nurse |
| Trace parents / health worker of infants who fail to attend after discharge | | ROP nurse |
Roles and responsibilities of the neonatology team and ophthalmologist in relation to treatment for ROP

- Explain treatment to parents
  - Verbal explanation, and written information
  - Ophthalmologist
  - Neonatologist

- Prepare infant for treatment
  - Systemic: national guidelines
  - Eye(s): national guidelines
  - Neonatologist
  - ROP nurse

- Monitor infant during treatment
  - Neonatologist or anaesthetist

- Document that treatment given in medical/nursing records
  - Ophthalmologist
  - Neonatologist/ROP nurse

- Give parents date for follow up
  - Ophthalmologist
  - ROP nurse

- Document date of next exam in medical/nursing records
  - Ophthalmologist
  - ROP nurse

- Contact parents if fail to attend for follow up
  - Ophthalmologist
  - ROP nurse
GUIDELINES FOR: Universal Eye Screening Including Retinopathy Of Prematurity In Newborns

### RETINOPATHY OF PREMATURITY

#### WHOM TO SCREEN?
Gestation ≤ 34 weeks Or Birth weight ≤ 2000 grams
Any preterm infant with risk factors:
- Cardiorespiratory support
- Chronic lung disease
- Exchange transfusion
- Poor post-natal weight gain
- Prolonged oxygen requirement
- Blood transfusion
- Respiratory distress syndrome
- Sepsis
- Apnea

#### PREVENTIVE FACTORS
- Antenatal steroids
- Restrict use of Oxygen
- If baby on Oxygen target SpO2 between 90-95%
- Use CPAP when required
- Early enteral nutrition (breast milk preferred)
- Aggressive nutrition therapy
- Following aseptic precautions
- Restrictive blood transfusion policy

#### AGGRAVATING FACTORS
- Small for gestational age
- Uncontrolled Use of Oxygen
- Patent ductus arteriosus
- Sepsis
- Inadequate weight gain
- Prolonged ventilation
- Transfusion of blood products

#### SCREEN AT 30 DAYS OF LIFE/AT DISCHARGE

**No ROP**
- Zone III mature
  - Yes
    - Follow up at 4 months of corrected age for ophthalmological examination
  - No
    - Follow up once in every 1-2 weeks till maturity

**ROP**
- Treatment required
  - Yes
    - Treatable with LASER
      - Yes
        - Do LASER and re-examine after 1 week for residual disease
      - No
        - Needs treatment
    - No
      - Follow up after 1 week

**Indications for treating ROP**

<table>
<thead>
<tr>
<th>Zone</th>
<th>Stage</th>
<th>Plus</th>
<th>Noplus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zone1</td>
<td>Stage1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zone2</td>
<td>Stage1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zone2</td>
<td>Stage2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zone2</td>
<td>Stage3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Follow the child every 6 months once till 5 years for refractory errors, squint and other ophthalmological problems.
LIST OF COLLABORATIVE INSTITUTIONS AND TECHNICAL RESOURCE PERSONS TO FACILITATE RBSK FOR ITS INITIATIVES IN SCREENING AND MANAGING CHILDREN WITH VISION IMPAIRMENT INCLUDING ROP:

1. Dr. R. P. Centre, All India Institute of Medical Sciences, New Delhi: Contact person - a) Prof. Dr. Pradeep Sharma, Email: drpsharma57@yahoo.com; b) Prof. Dr. Parijat Chandra, Email: parijatchandra@gmail.com
2. Postgraduate Institute of Medical Education & Research, Chandigarh: Contact person - Prof. Dr. Mangat R Dogra, Email: drmangatdogra@gmail.com
3. L V Prasad Eye Institute, Hyderabad: Contact person - a) Prof. Dr. Gullapalli N Rao b) Dr. Subhadra Jalali, Email: subhadra@lvpei.org c) Dr. Ramesh Kekunnaya, Email: drrk123@gmail.com
4. Sankara Nethralaya (Main Campus), Chennai: Contact person - a) Dr. T S Surendran Email: drtss@snmail.org
5. Calcutta Medical Research Institute and Hospital: Contact person - a) Dr. Pranab Das, Email: drpranab2008@gmail.com
6. Narayana Nethralaya, Eye Hospital Bangalore: Contact person - a) Dr. Anand S Vinekar, Email: anandvinekar@yahoo.com
7. Aravind Eye Hospital, Madurai: Contact person - a) Prof. Dr. P. Vijayalakshmi, Chief-Paediatric ophthalmology, Email: p.vijayalakshmi@aravind.org
8. All India Institute of Medical Sciences, New Delhi: Contact person - a) Prof. Dr. Ashok Deorari
9. Institute of Post Graduate Medical Education and Research: Contact person - a) Prof. Dr. Suchandra Mukherjee, Email: drsmukherjee70@gmail.com b) Dr. Pranab Das, Email: drpranab2008@gmail.com
10. Chetana Charitable Trust, Chennai: Contact person - a) Dr. Namita Jacob, Program Director, Email: namitaj@yahoo.com
11. Indian Institute of Public Health, Hyderabad: Contact person - a) Prof. Dr. GVS Murthy b) Dr. Rajan Shukla, Email: rajan.shukla@iiphh.org

International Faculty:

- Prof. Dr. Lea Hyvarinen: Paediatric ophthalmologist at University of Dortmund & Univ. of Helsinki. Developed LEA Vision Tests for assessment & screening of children's vision. (lea.hyvarinen@lea-test.fi) & Rex Temple: rtemple@leatest.com
- Prof. Clare Gilbert: Paediatric ophthalmologist and International Eye Health at London School of Hygiene and Tropical Medicine. (Clare.Gilbert@lshtm.ac.uk)